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Chapter 1. 
Introduction 

Introduction 
Allogeneic bone marrow transplantation and T-cell depletion 
Allogeneic bone marrow transplantation (BMT) is the treatment of choice for various, malignant 
and nonmalignant hematological diseases.1"6 
During and after successful allogeneic BMT both the hematopoietic and the immune system 
of the recipient are gradually replaced by the lymphohematopoietic system of the marrow donor. 
Usually complete donor chimerism has been observed after allogeneic BMT, i.e. all evaluated 
lymphohematopoietic cells are of donor origin. The coexistence of donor and recipient lympho­
hematopoietic cells post-BMT has been defined as mixed chimensm.9 
Success of allogeneic BMT is often limited by post-transplant complications such as graft-
versus-host disease (GVHD), graft rejection or leukemic relapse. The major problem after 
allogeneic BMT is GVHD that is associated with a high incidence of fatal infections due to 
prolonged duration of a severely compromised immune state. GVHD is mainly caused by the donor 
T-lymphocytes present in the marrow inoculum. Effective in vitro depletion of T-lymphocytes, 
achieved by immunological or physical separation techniques, clearly reduces the incidence and 
severity of GVHD.10"15 The incidence of moderate to severe acute GVHD in recipients of an 
unmanipulated H LA matched sibling donor graft varies from 40 to 50% compared to 10 to 15% 
after transplantation with a T-cell depleted graft.16"19 T-cell depletion, however, is associated with 
an increased risk of graft failure and of leukemic relapse, especially in patients with chronic 
myeloid leukemia (CML).1214·15·1820"24 
Relapse rate after allogeneic bone marrow transplantation; 
influence of T-cell depletion « 151β2°-2β 
No T-cell depletion T-cell depletion Nijmegen 
range % t range % t % j 
AMLCR1* 12-20 30-40 39 
ALLCR1-2 6-28 29-40 32 
CMLCP1 6-25 25-65 39 
* AML CR1 acute myeloid leukemia in first complete remission, 
ALL CR1-2 acute lymphoblastic leukemia in first and second complete remission, 
CML CP1 chronic myeloid leukemia in first chronic phase 
f Numbers are reported probabilities of relapse г 2 years after BUT. 
t Numbers are probabilités of relapse 3 years after BMT. 
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Moreover, incidences of mixed chimensm, varying from 51% to 100% have been reported after 
T-cell depletion Ä 3 3 This is clearly higher compared to the incidence of mixed chimensm after 
BMT with non-T-cell depleted grafts ^ 3 4 3 5 studies have demonstrated that mixed chimensm, 
even with high percentages of autologous cells, does not necessanly predict relapse 333436*> 
Since 1981 more than 400 patients, treated at the University Hospital Nijmegen, have received 
allogeneic bone marrow partially depleted of T-lymphocytes to prevent GVHD T-cell depletion 
was performed by density gradient centnfugation followed by counterflow centnfugation using 
a single chamber rotor or a four-chamber rotor ^ 3 9 To attain a fixed number of 1 0x10s T-cells 
/kg patient body weight in the graft, lymphocyte fractions were added to the maximally depleted 
graft fraction From 19Θ6 onwards the standard conditioning regimen, consisting of cyclophos­
phamide and fractionated total body irradiation was intensified by adding anthracyclines in order 
to reduce relapse rate In the patients treated with anthracyclines the probability of relapse was 
significantly lower compared to the historic control group Transplant related mortality did not 
increase by the addition of anthracyclines, resulting in a significantly higher probability of disease 
free survival in this study group 4 M 2 
Donor lymphocyte transfusions for treatment of relapse after BMT 
CML is a malignant stem cell disorder charactenzed cytogenetically by the Philadelphia (Ph) 
chromosome a specific translocation of the Abelson (ABL) oncogene on chromosome 9 to the 
breakpoint cluster region (BCR) on chromosome 22 At the molecular level this translocation can 
be detected by polymerase chain reaction (PCR) of BCR-ABL fusion molecules, after isolation 
of cellular RNA a reverse transcnptase reaction (RT) is performed followed by amplification by 
PCR After Southern transfer the PCR product is then analyzed by hybndization using a radio-
actively labeled c-ABL oligonucleotide 
As mentioned above, T-cell depletion of the graft increases the nsk of relapse, especially in 
CML patients21 Part of the reduced antileukemic activity of T-cell depleted grafts can be explained 
by the reduced incidence of GVHD In CML patients an additional antileukemic effect mediated 
by T-lymphocytes, independent of GVHD has been suggested21 Relapse rates in patients 
transplanted for CML in first chronic phase of 40-60% have been reported after T-cell depletion 
compared to 10-20% after BMT with unmanipulated grafts 1 S 1 8 4 3 
One of the treatment options for CML patients relapsed after BMT is Interferon alpha (IFNa), 
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which can achieve a cytogenetic remission in a minonty of the patients While IFNa may prolong 
survival, it is not a curative treatment ""45 Second BMT with unmanipulated marrow from the 
original donor is a potentially curative therapeutic option but is associated with a high risk of 
treatment related mortality ^47 
In 1990 the first three patients were reported who were successfully treated for relapse after 
BMT with leukocyte infusions from the onginal marrow donor All 3 patients achieved complete 
hematologic and cytogenetic remission № Two years later Cullis et al desenbed 2 patients with 
cytogenetic relapse of CML after BMT, who achieved cytogenetic and subsequently molecular 
remission of CML after donor leukocyte infusions * Recently various studies descnbmg successful 
treatment of CML patients relapsed after BMT with donor leukocyte transfusions have been 
published so^> In a review of the results reported by 27 transplant centers in the European Group 
for Blood and Marrow Transplantation (EBMT) 54 out of 75 évaluable CML patients (73%) achieved 
complete hematologic and cytogenetic remission with this immune treatmentω Especially in 
patients with relapse of CML after BMT, donor lymphocytes are capable of exerting a graft versus 
leukemia (GVL) effect In the EBMT study a close association between the development of GVHD 
and/or myelosuppression after donor leukocyte infusions and the GVL effect was found The 
response rate was 91% in CML patents developing GVHD and/or myelosuppression Conversely, 
45% of the patients without GVHD and/or myelosuppression responded favorably to this treatment 
Allogeneic BMT across the ABO barrier 
Major ABO incompatible BMT is the situation in which the recipient has the potential to express 
anti-Α and/or anti-B antibodies against donor AB antigens Major ABO incompatibility between 
recipient and donor occurs in about 10-15% of HLA matched allogeneic bone marrow transplan­
tations Major ABO incompatibility is not an obstacle to successful outcome after BMT No 
increased nsk of graft rejection, GVHD or mortality related to ABO incompatibility have been 
observed Κ 5 7 Major ABO incompatibility cames the nsk of an acute hemolytic transfusion reaction 
by anb-A or anti-B antibodies of recipient ongin at the time of infusion of the donor marrow This 
can be prevented by reduction of the antibody titers in the recipient or by removal of erythrocytes 
from the graft5 f w o Immunohematologic complications like delayed hemolytic anemia, delayed 
onset of erythropoiesis and pure red cell aplasia (PRCA) have been reported after major ABO 
incompatible BMT "^ 9 Delay in erythropoiesis after major ABO incompatible BMT can be 
explained by the interaction of anfa-A or anti-B antibodies with donor erythroid precursors 
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expressing the A and/or В antigens 70 
In minor ABO incompatibility the donor has the potentat to express anb-A and/or ant-B against 
AB antigens on recipient erythrocytes Several studies have reported the early appearance (1 to 
6 weeks) after BMT of antirecipient antibody sometimes causing manifest hemolysis Ш 7 1 7 3 This 
phenomenon has been descnbed after minor ABO solid organ transplantation as well and is 
explained by the adoptive transfer of donor lymphocytes in the marrow or solid organ graft74_77 
The disappearance of this donor antreapient antibody from 3 months after BMT onward suggests 
the induction of tolerance for the recipient A and/or В antigens which are widely distributed also 
in non-hematopoietjc tissues X7iT7 An alternative explanation could be the absorption of antibody, 
produced by donor lymphocytes, by recipient tissues expressing the A and/or В antigens 
Techniques to evaluate hematopoietic chimerism after BMT 
To distinguish donor and recipient lymphohematopoietic cells after allogeneic BMT several 
techniques can be used such as cytogenetic analysis, determination of DNA restnction fragment 
length polymorphisms (RFLP), polymerase chain reaction (PCR)-based determination of vanable 
numbers of tandem repeats (VNTR) or PCR amplification of microsatellites, analysis of 
immunoglobulin allotypes, in situ hybridization (ISH) in case of sex mismatched transplant situation 
or red blood cell antigens ^ 7 " 8 
In this thesis a newly developed sensitive technique to determine red blood cell populations 
has been used to study the course of recipient erythrocytes after BMT and after donor lymphocyte 
infusions and to assess the incidence of mixed chimensm from 6 months after BMT onwards 
We used this technique to monitor donor erythrocyte engraftment especially in the case of major 
ABO incompatibility between recipient and donor 
Analysis of host and donor erythrocyte populations early after BMT requires an adapted 
transfusion policy ю Blood samples for red cell phenotypmg are drawn from all potential BMT 
candidates, preferentially before any erythrocyte transfusion is given As soon as the marrow donor 
is known, patient and donor are phenotyped for the following red cell antigens ABO, CcDEe, 
MNSs, P1, Kk, Kp" Kp", Fya Fyb, Jk" Jk", Lua Lu" Afterwards marker antigens, ι e antigens 
present in the donor and absent in the host and vice versa, are determined and erythrocytes of 
blood group О lacking the marker antigens are transfused Both recipient and donor markers, 
recipient marker only, donor marker only or no markers were available in about 60, 20,10 and 
10 percent of the BMT patients respectively 
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Initally differential agglutination techniques were used to measure host and donor erythrocyte 
populations Although the results were informative, limited sensitivity and reproducibility were 
obvious disadvantages of these semiquantitative techniques M Since 1986 a fluorescent 
microsphere method gradually replaced the agglutination techniques ю In this assay erythrocytes 
are first incubated with an IgG antibody directed against the marker under investigation After 
several washings, anti-human IgG coated fluorescent microspheres are added Contact between 
red blood cells and microspheres is enhanced by centnfugation Marker antigen positive 
erythrocytes are labeled intensively with fluorescent microspheres and can be visualized and 
counted under a fluorescence microscope The sensitivity level of this assay is one positive cell 
per 10000 negative cells This technique evaluates only the erythroid lineage and this may not 
reflect the hematopoietic chimensm of the other cell lineages Another disadvantage is the 
relatively long life-span of mature erythrocytes, which may mask rapid processes like graft 
rejection 
Conventional cytogenetic analysis can only be performed on metaphase cells, which limits the 
number of available cells The sensitivity level of cytogenetic analysis for the detection of a minor 
cell population is dependent on the number of cells studied, e g examining 32 cells allows the 
detection of a level of 9% mosaicism with 95% confidence Μ Bone marrow cells are harvested 
directly and/or after a 24-hour culture without mitogens Metaphase cells in the bone marrow 
predominantly belong to the myeloid and erythroid lineage Cytogenetic analysis of peripheral blood 
is performed after cultunng of whole blood in the presence of phytohemagglutinin resulting in a 
proliferation of T-lymphocytes If patient and donor are of different sex, identification of the sex 
chromosomes can be applied In case of sex match, the applicability of cytogenetic analysis in 
studying chimensm is dependent on heteromorphisms of the autosomal chromosomes between 
recipient and donor These can be found in 20-25% of the donor/recipient sibling pairs using 
different banding techniques An advantage of chromosome studies after BMT is the possibility 
to look for cytogenetic abnormalities, which were present in the malignant clone of the recipient 
at diagnosis before BMT 
In case of a sex difference fluorescence in situ hybndization can be applied to discriminate 
between patient and donor cells œ This technique is performed on interphase cells which allows 
the examination of up to 400 nucleated cells A signal that discnminates one to five cells out of 
400 cells is considered background This limits the sensitivity of this technique to a level of one 
percent 
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Following digestion with restriction endonucleases, variations in DNA sequences among 
individuals result in DNA fragments of differing lengths known as RFLPs. Subsequently these 
fragments are separated according to their molecular weight by electrophoresis and transferred 
to a membrane (Southern blotting). Hybridization with radiolabeled probes is then performed to 
visualize the fragments.7M1 Patients and sibling donors are virtually always distinguishable using 
a panel of restriction endonucleases and probes. The sensitivity of this assay is 5-10%. 
A more sensitive molecular method to study mixed chimerism is PCR amplification of regions 
with a variable number of tandem repeats (VNTR) or microsatellites. The human genome contains 
hypervariable regions, which are highly polymorphic due to variation in the number of tandemly 
repeated sequences in different alleles. Microsatellites are short, interspersed repetitive DNA 
sequences, which are highly polymorphic. Studying multiple VNTR loci or microsatellites, 
discrimination between patient and sibling donor is almost always possible. The reported sensitivity 
level of these techniques varies from 0.1-5% depending partly on the number of cells studied.83,64 
DNA based techniques are applicable to all nucleated cells. This gives the opportunity, after 
isolation of subsets of blood cells, to study mixed chimerism in these cell populations 
simultaneously.91,92 
Outline of investigation 
Chapter 2 contains observations on donor erythrocyte repopulation measured with the fluor­
escent microsphere method from 0.5 to 6 months after BMT. The course of autologous 
erythrocytes was studied in this time period and compared between patients who relapsed or 
remained in remission during follow up. In a previous study the fluorescent microsphere method 
has been applied to study erythrocyte survival in orthopaedic patients. These patients received 
one erythrocyte transfusion positive for an antigen that was negative in the patient The transfused 
erythrocytes were detectable for a period of maximally 150 days.93 Extrapolating this 150 days 
survival to the course of recipient erythrocytes after BMT, mixed erythrocyte chimerism was defined 
from 6 months after BMT onward. In patients transplanted between 19B1 and 19ΘΘ the incidence 
of mixed erythrocyte chimerism was studied at various time points from 6 months onward. The 
follow up of mixed red cell chimeras was compared between patients with and without relapse 
more than β months after BMT. 
Chapter 3 describes the results of a retrospective analysis of 144 patients transplanted in 
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Nijmegen from 1981 to 1991. In this time period three consecutive conditioning regimens were 
applied. The influence of the conditioning regimen on the incidence of mixed erythrocyte chimerism 
was studied. The incidence and severity of both acute and chronic GVHD were compared between 
the three patient groups. The relation between the incidence of mixed erythrocyte chimerism and 
the presence of acute and chronic GVHD was addressed. 
The significance of mixed erythrocyte chimerism in CML and acute leukemia was studied. This 
was focussed on a relation between the percentages of autologous erythrocytes from 6 months 
after BMT onward and the occurrence of relapse. 
Studying the course of autologous erythrocytes was one of the ways to monitor the effects of 
donor leukocyte transfusions, administered to 6 CML patients who relapsed after BMT. This 
treatment modality and its results are described in Chapter 4. Chimerism was studied in these 
patients using erythrocyte and cytogenetic markers. Monitoring of residual disease was performed 
by cytogenetic analysis of the Ph chromosome and by PCR of the BCR-ABL fusion molecules. 
In Chapter 5 donor erythrocyte repopulation was analyzed in 30 patients after major ABO 
incompatible BMT and compared to a control group of 58 patients who received an ABO 
compatible or minor incompatible graft. Pretransplant anti-donor, anti-Α and anti-B antibody titers 
and the course of these antibodies after BMT were compared between those patients who 
developed pure red cell aplasia (PRCA) and those with timely recovery of donor erythropoiesis. 
The incidence of immunohematologic complications in the major ABO incompatible group was 
compared to the incidence reported in the literature to study a possible effect of the elutriation 
of the graft. 
The course of anti-donor, anti-Α and anti-B antibodies after major ABO incompatible BMT was 
compared between recipients of elutriated and non-elutriated grafts in a study presented in Chapter 
6, which was performed at the Johns Hopkins Oncology Center. 
In the same study the occurrence of the antirecipient antibody early and late after BMT was 
analyzed and compared between recipients of minor ABO incompatible elutriated and non-
elutriated marrow grafts. 
In our experience the microsphere method is a very sensitive and relatively simple technique 
to monitor recipient and donor erythropoiesis after BMT and after treatment with donor leukocyte 
transfusions. 
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Host and donor erythrocyte repopulation patterns 
Summary 
Analysis of erythrocyte populations, using red blood cell antigen differences between host and 
donor as marker, was performed with a sensitive fluorescent microsphere assay to monitor marrow 
engraftment and mixed red cell chimensm after allogeneic bone marrow transplantation (BMT) 
An adapted transfusion policy, using marker negative erythrocyte transfusions, was required for 
this analysis In all patients the marrow graft was depleted of lymphocytes by counterflow 
centnfugation Thirty-seven patients were évaluable for donor repopulation at one or more points 
in the first 6 months after BMT At 0 5 month donor erythrocytes were detectable in 19 out of 22 
patients 
At 6 months donor erythrocytes were detectable in 100% of the évaluable patients In the first 
3 months after BMT the average donor erythrocyte repopulation in recipients of major ABO 
mismatched transplantations was delayed Thirty-eight patients were évaluable for chimensm at 
6 months or later after BMT A high incidence of mixed red cell chimensm was observed varying 
from 50% to 71% at different points of analysis Mixed red cell chimensm with low percentages 
(<1%) of host cells was not related with relapse, nor did high percentages (>10%) of host cells 
necessarily indicate relapse 
Introduction 
Effective T-cell depletion of the marrow graft can prevent acute graft-versus-host disease after 
BMT 12 A high incidence of mixed chimensm has been reported after T-cell depletion in BMT 
3 A 5
 To distinguish host and donor type lymphopoietic and hematopoietic cells after allogeneic 
bone marrow transplantation several techniques such as cytogenetic analysis, determination of 
DNA restnction fragment length polymorphisms (RFLP), analysis of immunoglobulin allotypes or 
red blood cell anbgens, can be used678·910 We have employed standard differential agglutination 
techniques to determine red blood cell populations after BMT " During an adapted transfusion 
policy, the results of these techniques were very informative However, with the previously used 
differential agglutination techniques donor erythrocytes were only detectable in a minority of the 
patients at 0 5 month after BMT Recently a much more sensitive technique for detection of minor 
erythrocyte populations, using fluorescent microspheres, has been descnbed 12 This report 
contains observations on donor erythrocyte repopulation measured with the fluorescent 
microsphere method from 0 5 to 6 months after BMT 
29 
Studies on donor and host erythrocyte populations 
Since all our patients received T-cell depleted donor marrow, we were interested in the 
incidence of mixed red cell chimerism at 6 months or later after BMT. Moreover we studied a 
possible correlation between autologous red cell patterns and relapse after BMT. 
Materials and Methods 
From May 1981 to May 1988 91 patients underwent an allogeneic bone marrow transplantation. 
In 90 patients the donor was a HLA-A, В and DR identical, mixed lymphocyte culture (MLC) 
negative sibling. One patient differed from the donor sibling in one A locus but the MLC was 
negative. The median age of the patients was 31 years (range 16-47). The indications for 
transplantation in these patients were acute myeloid leukemia, n=24; acute lymphoblastic 
leukemia, n=28; chronic myeloid leukemia, n=29; myelodysplastic syndrome, n=6; other malignant 
disease, n=2; and severe aplastic anaemia, n=2. 
Transplant procedure. 
In all patients the standard conditioning regimen consisted of cyclophosphamide 60 mg/kg on 
days -6 and -5 and of fractionated total body irradiation of 4.5 Gy/d on days -2 and - 1 , administered 
with a 18 MV photon beam linear accelerator. The midline average dose rate was 4.1 ± 0.5 
cGy/min in the first 60 transplanted patients and 12.3 ± 3.2 cGy/min in the following 31 patients. 
Lungs and eyes were shielded using individually adapted lead blocks. The corrected median lung 
dose was 780 ± 70 cGy and 720 ± 70 cGy for the patients receiving the lower and higher midline 
average dose rate respectively. 
In the last 41 patients anthracyclines, either daunorubicin 26 mg/nWd or demethoxydaunorubicin 
7 mg/rrWd, given as a continuous intravenous infusion for 6 days from day -7 to - 1 , were added 
to the conditioning regimen. 
On day 0 the patients received donor marrow depleted of 9 8 % of lymphocytes. This was 
achieved by density gradient centrifugation followed by counterflow centrifugation.13 Less than 
10e residual erythrocytes were present in the marrow graft. 
Immunoprophylaxis. 
Of the first 11 patients 9 patients received only methotrexate (MTX) as immunoprophylaxis 
postgrafting14 and two patients had no prophylaxis. Subsequent patients were treated with either 
MTX and cyclosporin A (n=34) or cyclosporin A only (η=46).15,1β 
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Erythrocyte markers. 
Analysis of host and donor erythrocyte populations early after BMT, using red blood cell 
antigens, requires an adapted transfusion policy.11 If a patient is considered a potential BMT 
candidate a blood sample for red cell phenotyping is frozen, preferentially before any erythrocyte 
transfusion is given. As soon as the donor is known, a complete red cell phenotyping of patient 
and donor is performed and differing antigens, i.e. marker antigens, if present, are determined. 
In Table I the availability of markers in the 91 transplanted patients is shown. We always attempted 
to give erythrocyte transfusions lacking the marker antigens. If it was impossible to give 
transfusions negative for both markers, donor marker negative blood was transfused. 
In case of blood transfusions unselected for the marker antigens, we assumed these 
transfusions to be marker positive. Considering a maximum survival of erythrocytes of 150 days, 
the marker percentages determined the first 150 days after the unselected transfusion were 
excluded from analysis. 
Table I. The availability of erythrocyte markers in 91 BMT patients 
No. of patients % 
Recipient and donor marker 58 64 
Only recipient marker 15 16 
Only donor marker β 9 
No markers β 9 
Markers unknown 2 2 
Analysis of erythrocyte markers. 
For the initial BMT proceedings in our institute, differential agglutination techniques were used 
to measure host and donor red cell populations.11 The disadvantages of these techniques are 
a limited sensitivity of about 1% and limited reproducibility because of intertechnologist variation. 
Since 1986 a fluorescent microsphere method gradually replaced the agglutination techniques.12 
In this assay red blood cells are first incubated with an IgG antibody directed against the marker 
antigen under investigation. After washing the erythrocytes several times, anti human IgG coated 
fluorescent microspheres are added. The contact between cells and microspheres is enhanced 
by centrifugaron. Marker antigen positive erythrocytes are labeled intensively with fluorescent 
microspheres and can be visualized and counted under a fluorescence microscope. The sensitivity 
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level of this assay is one positive cell per 10000 negative cells. Blood group antigens examined 
in this study are A1, A2, B, DCcE, Jk3, Jk", Fy", Fy", K, MSs and Kpa. Time schedule for analysis 
was 0.5, 1, 2, 3, 6, 9 and 12 months after BMT and annually thereafter. 
Statistical analysis. 
Statistical analysis was performed by the Fisher's exact test and the Student's t-test. 
Definitions. 
Mixed chimerism was defined by the coexistence of host and donor type hematopoietic cells 
in the recipient at 6 months or later after BMT; complete donor chimerism was defined by the 
presence of donor type hematopoietic cells only in the recipient from 6 months after BMT onwards. 
Results 
Donor erythrocyte repopulation 
Data on donor erythrocyte repopulation from 0.5 to β months after BMT, as measured with the 
microsphere method, are given in Table II. 37 patients were studied at one or more points after 
BMT. Patients were considered not to be évaluable mainly because of lack of donor marker or 
because they received unselected transfusions within 150 days before analysis. If a patient 
relapsed, data on donor erythrocytes after date of relapse were excluded from analysis. 
As shown in Table II donor cells were detectable in 86% of the évaluable patients at 0.5 month 
after BMT. Data from differential agglutination techniques at 0.5 month after BMT revealed donor 
erythrocytes only in five out of 24 évaluable patients (data not shown). From 0.5 to 6 months after 
BMT the percentages of donor red cells increased steadily from a median of 0.04% donor cells 
at 0.5 month to 88.8% at 6 months (Table II). 
Donor erythrocyte repopulation in major ABO mismatched transplantations 
At 1,2 and 3 months after BMT donor erythrocytes were not detectable with the microsphere 
method in four, one and two patients respectively. All these patients were recipients of major ABO 
mismatched transplantations. Fig 1 shows the course of donor red cell repopulation of recipients 
with or without major ABO mismatched transplantations from 1 to 6 months after BMT. Recipients 
of major ABO mismatched transplantations showed a trend for delayed donor repopulation. This 
was significant at 3 months (p=0.03). 
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Table II. Donor erythrocyte repopulation 0 5-6 months after BMT 
analyzed with the microsphere method 
Months 
after BMT 
0.5 
1 
2 
3 
6 
No. of 
patients 
22 
22 
23 
25 
26 
%of 
patients with 
donor RBC* 
86 
82 
96 
92 
100 
%of 
donor RBC 
median/range 
0.04/0 01-0.66 
3.21/0.04-19.7 
27 8/0 02-71.9 
59 5/0.23-90.1 
88 8/1.53-100 
'RBC red blood celle 
'U donor erythrocytes 
1 0 0
Ί 
90-
80 
70 
60 
50-1 
¿0 
ЗОН 
20 
10 
Major ABO msmatdi 
τ 1 1 1 г 
2 3 4 5 6 
months after BMT 
Fig 1 Donor erythrocyte repopulation from 1 to 6 months after BMT in recipients with and without major ABO mismatched 
transplantations Numbers of patents major ABO/no major ABO, 1 month 13/9,2 months 11/12, 3 months 11/14, 
6 months 9/1Θ Percentages shown are mean values ± standard error of the mean (SEM) 
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Autologous erythrocytes in the first 6 months after BMT 
The course of autologous erythrocytes in the first 6 months after BMT measured with the 
microsphere method was studied in 33 patients (Fig 2A and 2B). The other patients were not 
évaluable mainly because of lack of host marker or because they received erythrocyte transfusions 
unselected for this marker. Only recently we have started to measure the percentages of host 
erythrocytes at day 0. These values therefore are only available in eight of the 33 patients. 
Because of previous transfusions negative for the host marker, values of less than 100% were 
observed. 
In patients with a follow up not complicated by relapse, a gradual decrease of autologous 
erythrocytes was observed (Fig 2A). Five of the évaluable patients relapsed (Fig 2B). In two of 
them the autologous red cells initially decreased but increased during follow up resulting in relapse 
a few months later. In two patients the autologous erythrocytes remained detectable in high 
percentages or even increased in the first 6 months. Only one patient showed a clear decrease 
of host erythrocytes shortly before she relapsed. 
autologous erythrocytes V. 
Fig 2. Course of autologous erythrocytes from 0.5 to 6 months after BMT. 
(A) no relapse during follow up, (B) relapse during follow up. 
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Mixed red cell chimerism 
Thirty-eight patients were évaluable for chimerism with the microsphere method at 6 months 
or later after BMT. Results on mixed chimerism are presented in Table III. Patients were excluded 
from analysis because of death from transplant related complications within the first 6 months, 
a relapse within the first 6 months, a follow up of less than 6 months or lack of markers. 
Table III. Red cell chimerism at 6 months or later after BMT 
analyzed with the microsphere method 
Months 
ifter BMT 
6 
9 
12 
24 
>24 
No. of 
patients 
26 
27 
27 
17 
8 
%of 
MC 
69 
63 
59 
71 
50 
patients 
CDC* 
31 
37 
41 
29 
50 
% of autologous RBC' 
in mixed chimeras 
median/range 
0.05/0.01-70.8 
0.07/0.01-81.6 
0.06/0.01-57.1 
0.51/0.02-66 
5.5/0.03-34.7 
* RBC: red blood cells 
* MC mixed chimerism, CDC' complete donor chimensm 
A high percentage of mixed chimeras was found at all points after BMT. The median 
percentages of autologous red cells demonstrate that most patients have only small amounts of 
autologous cells in circulation. Combining the results of the microsphere method at 6, 9 and 12 
months 20 patients were mixed chimeras and 16 patients complete donor chimeras. Between 
these two groups there were no differences in diagnosis (data not shown). In the 14 patients who 
received anthracyclines in the conditioning regimen and were irradiated with an average dose 
rate of 12.3 cGy/min, a lower incidence of mixed chimerism (36%) was found than in the 17 
patients without anthracyclines during conditioning and an average dose rate of 4.1 cGy/min 
(70%). This difference, however, was not significant (p=0.057). Five patients received anthra-
cyclines and an average dose rate of 4.1 CGy/min. Three of them were mixed chimeras and two 
patients were complete donor chimeras. 
Follow up of the mixed red cell chimeras 
Fig ЗА and В shows the follow up of 25 patients, being mixed chimeras at first point of analysis, 
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6 months or later after BMT. Different patterns in the course of autologous red cells can be 
recognized in 21 patients without relapse (Fig ЗА). Ten patients are stable mixed chimeras with 
low percentages (<1%) of autologous cells at different moments of analysis. Three patients are 
stable mixed red cell chimeras as well but their percentages of autologous cells are obviously 
higher (> 10%) and increase in time in two of them. Cytogenetic analysis of peripheral blood and/or 
bone marrow has confirmed the results of the erythrocyte antigen analysis in these three patients. 
RFLP analysis has only been performed in one of the three patients but gives similar results. Six 
patients have converted to complete donor chimeras. Four of them beyond 6 months after BMT, 
two patients beyond 12 and 24 months respectively. These patients have remained complete donor 
chimeras during follow up. Finally, in two patients, initially mixed chimeras, autologous erythrocytes 
were no longer detectable at next point of analysis. However, autologous red cells reappeared 
in small quantities during further follow up without clinical evidence of relapse. 
autologous erythrocytes V. 
Ю0 
6 9 12 » I I 36 46 60 72 6 9 12 II 24 36 48 60 72 
months after BMT 
Fig 3 Follow up of patients being mixed red ceH chimeras at first point of analysis 6 months or later after BMT 
(A) No relapse during follow up, (B) Relapse during follow up 
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Four mixed chimeras relapsed (Fig 3B) Two of them had repeatedly high percentages of 
autologous red cells, confirmed by cytogenetic analysis of peripheral blood and bone marrow, 
before relapse In the other two patients the autologous erythrocytes increased markedly in the 
penod before relapse, in one of them after an initial decline 
Follow up of the complete donor red cell chimeras 
Twelve patients were complete donor chimeras at first point of analysis 6 months or later after 
BMT One patent, being a complete donor chimera at 6 months, converted to a mixed chimera 
with 0 02% and 0 01% autologous red cells at 9 and 12 months respectively All other patients 
who were analyzed 2 to 4 times during follow up (n=7) proved to be stable complete donor 
chimeras None of the complete donor chimeras was a mixed chimera when bone marrow cells 
were assessed by cytogenetic analysis (data not shown) 
One patient, who was a complete donor chimera at 12 months, relapsed one month later 
Discussion 
We analyzed erythrocyte populations, using red blood cell antigen differences between host 
and donor, to study marrow engraftment and mixed red cell chimensm after allogeneic bone 
marrow transplantation Agglutination techniques and more recently a fluorescent microsphere 
method were used These assays are simple and results are available within a day The 
advantages of the microsphere method over the agglutination techniques are, besides accuracy 
and reproducibility, a higher sensitivity of 0 01% n A potential disadvantage of red blood cell 
antigen analysis is the fact that only one cell lineage is studied Cytogenetic analysis of penpheral 
blood and/or bone marrow and determination of RFLPs are widely used to distinguish patient and 
donor lymphopoietic and hematopoietic cells after BMT M1° The sensitivity of cytogenetic analysis 
for the demonstration of minor cell populations is limited by the number of metaphases analyzed n 
In the post-transplantation penod it may be impossible to obtain sufficient dividing cells RFLP 
is a highly informative technique with a sensitivity of 1-10% А™ю in contrast to cytogenetic 
analysis it does not depend on dividing cells, but it requires high quality technical staff and 
equipment and it is also time consuming 
Analysis of erythrocyte populations requires an adapted transfusion policy, giving marker 
negative erythrocyte transfusions This condition was not always fulfilled, especially in the first 
25 transplanted patients In case of unselected transfusions we considered the patient not 
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évaluable in the first 150 days after transfusion. These 150 days originated from an erythrocyte 
survival study we performed in orthopaedic patients with the fluorescent microsphere method. 
These patients received one erythrocyte transfusion positive for an antigen that was negative in 
the patient. The transfused erythrocytes were detectable for a period of maximally 150 days after 
the transfusion.18 Taking this survival into account we defined mixed chimerism of erythrocyte 
populations from 6 months after BMT onwards. 
With the fluorescent microsphere method we were able to detect donor erythrocytes in 86% 
of the évaluable patients at 0.5 month after BMT. None of the recipients of major ABO mismatched 
transplantations underwent plasma exchange or immunoadsorption. As pointed out by Sniecinski 
et al1 Э and Revirón et al20 we found that major ABO mismatched transplantations showed a trend 
for delayed donor repopulation and increased red cell transfusion requirements (data not shown). 
However, in contrast to Sniecinski et al1 θ, all patients with major ABO mismatched transplantations 
in our study repopulated well at 6 months after BMT. 
A gradual decrease of autologous erythrocytes in the first 6 months after BMT was seen in all 
patients whose follow up was uncomplicated by relapse. A progressive increase of autologous 
red cells within the first 6 months was associated with relapse. Yam et al 7 observed this same 
pattern in two patients, using RFLP of peripheral blood cells. Knowlton et al '° described two 
patients with reappearance of peripheral autologous cells in increasing percentages. Only one 
of them has relapsed. One of our patients relapsed while host red cells decreased. This might 
suggest a clonal expansion of a more committed stem cell not involving the erythroid lineage in 
this particular patient. 
A high incidence of mixed red cell chimerism was found in this study. This is certainly a 
consequence of T-cell depletion as has also been described by Bretagne et a l \ De Witte et al3 
and Ferrara et al.5 Because of their lower number in the graft, mature T-lymphocytes are less 
capable of destroying host lympho-hematopoietic cells, which have survived the conditioning 
regimen. The low incidence of graft-versus-host disease, thanks to T-cell depletion,1,215 may 
amongst others be responsible for a higher incidence of autologous reconstitution. Another 
important reason for the high number of mixed chimeras is the 0.01% sensitivity of the fluorescent 
microsphere method. 
No clinical evidence for leukemic recurrence was found in stable mixed chimeras with low 
percentages (<1 %) of autologous cells (n=10) or mixed chimeras, who converted to complete 
donor chimeras (n=6). Reappearance of small numbers of autologous cells in one patient who 
was initially a complete donor chimera, and in two patients who had been mixed chimeras earlier 
in their posttransplantation course but subsequently lost the host cells, was not associated with 
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leukemic relapse as well It is important to stress that mixed chimensm with less than 1% 
autologous cells can not be detected with cytogenetic analysis and RFLP Therefore, the nsk of 
relapse after BMT in this group of mixed chimeras can only be evaluated with red cell markers 
A marked increase of autologous cells was associated with relapse in two mixed chimeras 
However, mixed chimeras with high (>10), sometimes even gradually increasing, percentages 
of autologous red cells did not relapse necessanly In three out of five mixed chimeras with this 
pattern the results of the red cell marker analysis were confirmed by cytogenetic analysis of bone 
marrow in one patient and of penpheral blood in two patients They have not relapsed 36, 48 and 
72 months after BMT respectively Petz et al21 and Branch et a l " desenbed similar patients with 
predominance of host red cells confirmed by cytogenetic analysis without clinical evidence of 
relapse 
Finally, we found a difference in incidence of mixed chimensm between the patients who 
received anthracyclmes and irradiation at a higher dose rate and the patients conditioned without 
anthracyclines and irradiated at a lower dose rate, but this difference was not (yet) statistically 
significant 
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Influence of the conditioning regimen 
Summary 
Three different conditioning regimens were applied to 144 patients undergoing allogeneic bone 
marrow transplantation (BMT) with HLA identical sibling marrow, depleted of lymphocytes by 
counterflow centrifugation. All regimens consisted of cyclophosphamide and fractionated total 
body irradiation (TBI). In 49 patients treated with regimen A the total TBI dose was 9 Gy. In 
regimen В the dose rate of TBI was increased and anthracyclines were added (n=65). Thirty 
patients received regimen С with a total TBI dose of 12 Gy but no anthracyclines. 
The different conditioning regimens did not influence the percentage of patients with detectable 
recipient CFU-GM prior to infusion of donor marrow. The incidences of mixed erythrocyte 
chimerism at 6 months after BMT were 73, 33 and 20% for regimen А, В and С respectively. The 
conditioning regimen influenced significantly mixed erythrocyte chimerism from 6 to 24 months 
after BMT. 
Both age and the conditioning regimen influenced significantly the incidence of acute graft-
versus-host disease (GVHD) (p=0.017 and 0.0001 respectively). Acute GVHD > 1 occurred in 
15, 29 and 77% of the patients treated with regimen А, В and С respectively. The incidence of 
acute and chronic GVHD was significantly higher in complete donor chimeras than in mixed 
chimeras (p< 0.001 and p<0.01). The probability of relapse was 43% in 32 and 18% in 43 good 
risk patients treated with regimen A and В respectively (p=0.07). Longer follow up is needed to 
draw conclusions about relapse in regimen С 
We postulated that a more intensive conditioning regimen resulted in a lower incidence of mixed 
erythrocyte chimerism, a higher incidence of acute GVHD and a trend to a lower relapse rate. 
Introduction 
Allogeneic BMT with marrow from a HLA identical sibling has proven to be an effective 
treatment option for patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia 
(ALL) and chronic myeloid leukemia (CML) in chronic phase.1-5 However, moderate to severe 
acute GVHD occurs in approximately 45% of recipients of HLA identical marrow grafts despite 
posttransplant immunosuppressive therapy and it is an important cause of morbidity and mortality 
after BMT.2 3 
T-cell depletion of the allogeneic graft can be accomplished by various methods. Effective 
methods clearly decreased the incidence of acute GVHD.64 Several studies have shown an 
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increased relapse rate after T-cell depletion, especially in patients transplanted for CML 39"11 
Moreover, incidences of mixed chimensm, varying from 51-100%, have been reported after T-cell 
depletion n16 This is clearly higher compared with the incidence of mixed chimensm after BMT 
with non T-cell depleted grafts 17 
Intensification of the conditioning regimen could be an option to eradicate more, both normal 
and leukemic, hematopoietic recipient cells 1B19 In our center all patients have received marrow 
grafts depleted of lymphocytes by counterflow centnfugation м This study descnbes three different 
conditioning regimens and their impact on the incidence of mixed erythrocyte chimensm A 
sensitive fluorescent microsphere assay was used to detect recipient and donor red cells21 In 
addition we compared the incidence of acute and chronic GVHO, the number of remaining colony 
forming units granulocyte/monocyte (CFU-GM) on the day of BMT and the probability of relapse 
in good nsk patients 
Materials and methods 
From May 1981 til January 1991 157 allogeneic bone marrow transplantations were performed 
with marrow from a HLA-identical sibling donor Retransplant, transplant for nonmalignant diseases 
and transplant with donors other than HLA-compatible siblings were excluded from analysis A 
total of 144 out of 157 transplantations were preceded by one of three following conditioning 
regimens All three conditioning regimens consisted of cyclophosphamide 60 mg/kg/day (days 
-6 and -5) and fractionated TBI (days -2 and -1) administered by a 18 MV photon beam accelerator 
(Saturne, CGR, Bue, France) Lungs and eyes were always shielded using individually adapted 
lead blocks In regimen A, applied in 49 patients from May 1981 till June 1986 TBI was 
administered in a dose of 4 5 Gy/day with a midline average dose rate of 4 1 ± 0 5 cGy/mm The 
corrected mean total lung dose was 7 9 ± 1 3 Gy Regimen В was used in 65 patients from 
October 1986 till January 1990 The TBI dose in this regimen was 4 5 Gy/day with a midline 
average dose rate of 12 3 ± 2 0 cGy/mm The corrected mean total lung dose was 7 1 ± 0 8 Gy 
In addition anthracyclines, either daunorubicin 156 mg/rrr2 or demethoxydaunorubicin 42 mg/m2, 
were administered as a continuous intravenous infusion for 3 to 6 days on days -7 to -2 Initially 
regimen С was confined to H LA mismatched transplants but since 1990 it was used as the 
standard conditioning regimen consisting of cyclophosphamide as desenbed above and TBI in 
a dose of 6 Gy/day with a midline average dose rate of 12 3 ± 2 0 cGy/mm The corrected mean 
total lung dose was 7 3 ± 1 1 Gy In addition to lung and eye shielding the kidneys were shielded 
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in these patients using individually adapted lead blocks A total number of 30 patients with a H LA 
identical donor was treated with this regimen 
On day 0 patients received donor marrow depleted of 98% of lymphocytes by density gradient 
centnfugation followed by counterflow centnfugation ж 
Patient and donor characteristics 
In order to compare the three conditioning regimens only the 144 patients with a H LA ABDr 
identical, mixed lymphocyte culture (MLC) negative sibling donor were evaluated The mean age 
of these patients treated with regimen А, В or С was 28 9, 32 2 and 35 7 years respectively 
Indications for transplantation per conditioning regimen are given in Table I 
Immunoprophylaxis 
Of the first 11 BMT patients nine patients received only methotrexate (MTX) according to the 
Seattle regimen22 and two patients had no immunoprophylaxis The next 34 patients were treated 
with the combination of cyclosponn A (CsA) and MTX CsA (3 mg/kg/day) was given by continuous 
intravenous (iv) infusion from day -1 to day 28, followed by CsA orally (9 mg/kg/day), with a gradual 
tapenng off after 6 weeks and discontinuation after 12 weeks MTX was given as weekly iv 
injections from week 5 till week 16 after BMT in a maximal weekly dose of 10 mg/m2 Ώ All other 
patients received only CsA in a schedule as descnbed above 
Erythrocyte markers 
The procedure followed to select erythrocyte markers and the adapted transfusion policy have 
been descnbed before24 Of the 144 évaluable patients both a recipient and donor marker were 
present in 83 cases (58%), only a recipient marker in 36 cases (25%), only a donor marker in 15 
cases (10%) and no markers or unknown markers because of previous erythrocyte transfusions 
in 10 cases (7%) In case of an erythrocyte transfusion unselected for the marker antigens we 
assumed this transfusion to be marker positive Considering a maximum survival time of 
erythrocytes of 150 days the marker percentages determined the first 150 days after the 
unselected transfusion were excluded from analysis 2S In this study measurement of host and 
donor red cell populations after BMT was performed by a fluorescent microsphere method21 In 
this assay red blood cells are first incubated with an IgG antibody directed against the marker 
antigen under investigation After washing the erythrocytes, fluorescent microspheres coated with 
anti-human IgG are added followed by centnfugation Marker positive erythrocytes which are 
intensively labeled with fluorescent microspheres can be visualized and counted under a 
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fluorescence microscope. The sensitivity level of this assay is one positive cell per 10000 negative 
cells (0.01%). Blood group antigens examined were A1, A2, B, CcDE, K, MSs, Jka Jk", F / F / 
and Kpa. Time points of analysis were 6, 9 and 12 months after BMT and at least once yearly 
thereafter. 
Table I. Clinical details on patients per conditioning regimen 
Conditioning regimen 
No. of évaluable patients 
mean age 
(range) 
Indications for BMT 
AMLCR1 
AML CR>1 
ALL CR1 
ALL CR>1 
CML CP1 
CMLAP 
MDS 
LyLy CR 
NHL 
MM 
Others* 
Good risk patients'* 
No. total / relapsed 
Follow-up (months)' 
Median (range) 
Time to relapse (months)0 
Median (range) 
A 
49 
28.8 
(15-53) 
15 
1 
10 
1 
7 
6 
1 
2 
6 
32/10 
74 
(0.25-118) 
11 
(5-55) 
В 
65 
32.2 
(16-46) 
12 
1 
15 
4 
16 
1 
5 
3 
2 
2 
4 
43/6 
33 
(1-58) 
11 
(3-24) 
С 
30 
35.7 
(13-47) 
4 
5 
1 
1 
2 
5 
1 
4 
5 
12/4 
13 
(1-18) 
8.5 
(6-16) 
AML = acute myeloid leukemia; ALL = acute lymphoblastic leukemia, CML = chronic myeloid leukemia, MDS = 
myetodysplastic syndrome, LyLy = Lymphoblastic lymphoma, NHL = non Hodgkin lymphoma, MM = multiple myeloma, 
CR = complete remission, CP = chronic phase, AP = accelerated phase 
' Mainly advanced stage leukemia. 
** Good nsk patents = AML CR1, ALL CR1, CML CP1. 
* Follow-up for non relapsed good nsk patients ends at day of death or day of evaluation. 
β
 For good nsk patients 
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CFU-GM assay 
At day 0 a bone marrow sample was taken from all patients to assess the number of residual 
host CFU-GM after marrow ablative therapy. This assay was performed as previously described.26 
Definitions 
Taking into account a 150-day survival time of recipient erythrocytes generated before BMT, 
mixed chimerism was defined by the coexistence of host and donor erythrocytes in the recipient 
at 6 months or later after BMT. Complete donor chimerism was defined by the presence of donor 
type erythrocytes only in the recipient from 6 months after BMT onwards. Patients were considered 
to be évaluable for acute GVHD if they survived at least 20 days after BMT. The clinical 
manifestations of acute GVHD occurring till day 100 posttransplant were classified according to 
the criteria described by Glucksberg et al.27 Acute GVHD > I was treated by adding corticosteroids 
to CsA prophylaxis. Patients were évaluable for the presence or absence of chronic GVHD if they 
survived at least 100 days after BMT. 
Statistical analysis 
The probability of relapse was calculated according to the Kaplan-Meier method from the day 
of BMT. Follow up ends on the day of evaluation (December 1. 1991). Statistical comparisons 
between curves were made using the log-rank test. Analysis of variance was done by ANOVA. 
Multivariate analysis was performed using logistic regression. Frequencies were compared using 
the Fisher's exact test or the χ2 test. 
Results 
Patient characteristics 
Age distribution was significantly different between the three conditioning regimens (ANOVA, 
p=0.008). The age of the patients at the time of BMT increased during the years (Table I). 
Graft characteristics 
The absolute number of T-cells in the marrow graft was significantly different between the 
patients treated with regimen А, В and С (ANOVA, p=0.0001) (Table II). The patients in group 
В especially received more T-cells but compared to transplantation with unseparated marrow grafts 
the numbers of T-cells were very low in all 144 patients. 
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Engraftment 
Five out of 144 patients died within 20 days after BMT and are not évaluable for engraftment. 
All remaining patients engrafted. One patient, treated with regimen B, rejected the marrow graft 
after initial engraftment 2 months after BMT. 
Table II. Incidence of GVHD per conditioning regimen 
Conditioning regimen 
T-cells (Mean ± SEM) 
(106/kg body weight) 
Acute GVHD: 
Grade 0 
I 
II 
Ill/TV 
Chronic GVHD: 
Absent 
Present 
A 
0.66 * 0.08 
n(%) 
39 (85) 
2(4) 
1(2) 
4(9) 
n(%) 
27(77) 
8(23) 
В 
1.42 i 0.08 
n(%) 
45(71) 
7(12) 
10(15) 
1(2) 
n(%) 
30 (57) 
23 (43) 
С 
0.89 ± 0.06 
n(%) 
7(23) 
19 (63) p<0.001 
2(7) 
2(7) 
n(%) 
13 (54) p=0.096 
11 (46) 
Incidence of mixed erythrocyte chimerism 
For each of the three conditioning regimens the total numbers of patients évaluable for mixed 
erythrocyte chimerism at 6 months or later after BMT are given in Table III. Patients were excluded 
from analysis because of transplant related mortality, relapse before or at time point of analysis 
or because a recipient marker was lacking. Initially we did not use the fluorescent microsphere 
method as routinely as we did during the last 5 years and this explains the lower number of 
observations in patients transplanted with regimen A at 6 and 9 months after BMT. 
During the years, initially using regimen A, subsequently regimen В and finally regimen C, the 
incidence of mixed red cell chimerism has decreased. The conditioning regimen influenced 
significantly the occurrence of mixed erythrocyte chimerism at 6, 9, 12 and 24 months after BMT 
(χ2 test, p<0.02 at all time points). The majority of mixed chimeras in regimen A and В showed 
only small percentages of circulating autologous erythrocytes; 0.22 /0.011-81.6 and 0.034 
/0.01-14.9 (median/range) for regimen A and В respectively from 6 till 24 months after BMT. For 
regimen С the number of observations is too low to draw conclusions. 
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Combining the results of the three regimens 27 patients were mixed and 47 complete donor 
chimeras from 6 till 12 months after BMT. We performed multivariate analysis to examine the 
influence of the conditioning regimen, age and the number of T-cells in the graft on the occurrence 
of mixed erythrocyte chimerism in this time period. The presence of autologous red cells was 
influenced significantly by the pretransplant treatment regimen (p=0.0004). Neither age (p=0.8) 
nor the number of T-cells in the graft (p=0.07) had a significant influence on the incidence of mixed 
erythrocyte chimerism. 
Table III. Incidence of mixed erythrocyte chimerism per conditioning regimen 
at 6 months or later after BMT. 
Time Regimen A Regimen В Regimen С 
(months) No.' %MC* No. %MC No. %MC 
6 11 73 36 33 15 20 
9 12 83 33 36 14 21 
12 15 73 32 28 13 30 
24 15 73 31 13 
# Total number of évaluable patents per time point 
* % MC= percentage of mixed erythrocyte chimeras 
The significance of mixed erythrocyte chimerism in CML and acute leukemia 
When the data of the three conditioning regimens were pooled 35 patients had an allogeneic 
transplantation for CML either in chronic phase (n=26) or in accelerated phase (n=9). Twenty-two 
of these 35 patients had a recipient marker and no signs of clinical or cytogenetic relapse within 
the first 6 months after BMT. Twelve out of these 22 patients showed neither hematological 
relapse nor cytogenetic abnormalities during further follow up. Ten out of 22 patients developed 
a cytogenetic relapse at 6 to 60 months after BMT. In four of them hematological relapse 
converged with cytogenetic relapse. Hematological relapse followed the recurrence of the Ph 
chromosome after 6 and 12 months in two patients. The other four patients repeatedly have had 
Ph chromosome positive metaphases in the bone marrow without signs of hematological relapse 
with a follow up of 8 to 32 months after the first reappearance of the Ph chromosome after BMT. 
Figure 1A and 1B show the course of autologous erythrocytes in the relapse and no relapse group 
respectively. Nine out of 10 patients in the relapse group had high (>10%) or increasing 
percentages of autologous cells at the time of relapse. In one patient, with a cytogenetic relapse 
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at 12 months, the percentages of autologous erythrocytes decreased from 1.33 to 0.34 and 
0.068% at 6, 9 and 12 months after BMT. One year later hematological relapse manifested itself 
with a percentage of autologous cells of 96.5%. In the no relapse group six patients had no 
detectable autologous erythrocytes at 3 to 6 time points of analysis. Five patients did have variably 
detectable autologous cells but only in percentages < 0.5%. The last patient had 0 014% recipient 
red cells at 6 months but no detectable recipient red cells from 9 to 48 months after BMT. 
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Fig 1. Course of autologous erythrocytes in CML patients from 6 months after BMT onward. 
(A) Cytogenetic relapse during follow up indicated by arrow ( n=10). 
(B) No cytogenetic relapse during follow up ( n=12). 
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Forty-two out of 69 patients transplanted for AML or ALL had a recipient marker and no 
recurrent disease within the first 6 months after BMT The majonty of patients (n=33) who did not 
relapse dunng further follow up, were either complete donor chimeras or stable mixed chimeras 
with percentages of autologous erythrocytes below 1% However, two patients transplanted for 
AML in CR1, have had repeatedly percentages of recipient red cells varying from 5 to 20% without 
evidence of relapse dunng a follow up of more than 9 years Moreover two patients in continuous 
complete remission, transplanted for ALL in CR1, have shown increasing percentages of 
autologous red cells up to 88 and 45 % with a follow up of 75 and 95 months respectively Nine 
out of 42 patients relapsed at 6 to 36 months after BMT In six of these cases (four AML in CR1, 
one ALL in CR1 and one ALL m CR3) no autologous erythrocytes were detectable at the time of 
relapse In two patients, both ALL in CR1, relapse was preceded by increasing percentages of 
autologous cells up to 70% One patient who relapsed at 9 months, had 3 5 and 4 3% recipient 
erythrocytes at 6 and 7 months after BMT 
Graft-versus-host disease 
The incidence and the seventy of acute GVHD could be assessed in 139 out of 144 patients 
conditioned with regimen А, В or С (Table II) Forty-eight patients developed acute GVHD grade 
I or more (34%), 28 patients had grade I and 13 patients grade II GVHD 
Looking at each of the regimens the incidence of acute GVHD grade I or more was 15, 29 and 
77 % for regimen А, В and С respectively (p<0 001) Although the incidence of acute GVHD in 
patients treated with regimen С was higher, 19 out of 23 patients had grade I, two patients grade 
II and two patients grade lll/IV GVHD Mu№vanate analysis showed a significant influence of both 
age (p=0 017) and the conditioning regimen (p=0 0001) on the incidence of acute GVHD The 
number of T-cells in the graft had no significant influence on the occurrence of acute GVHD in 
multivariate analysis (p=0 2) 
The majonty of patients treated with regimen A received both MTX and CsA as 
immunoprophylactic treatment in contrast to patients conditioned with regimen В who received 
only CsA However, the incidence of acute GVHD grade I or more was not significantly different 
between these two patient groups (p=0 08) All patients treated with regimen В and С received 
CsA only as immunoprophylaxis, nevertheless the incidence of acute GVHD was significantly 
higher in the latter group (p<0 001) 
The presence or absence of chronic GVHD could be evaluated in 112 patients The overall 
incidence of chronic GVHD was 38% and the incidence per regimen 23, 43 and 46% for regimen 
А, В and С respectively (p=0 095) (Table II) In the majonty of cases chronic GVHD was limited 
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to the skin and of mild to moderate seventy No significant influence of age, the conditioning 
regimen or the number of T-cells in the graft on the incidence of chronic GVHD could be detected 
by multivariate analysis 
We assessed the relation between GVHD and mixed chimensm The results of the three 
conditioning regimens were combined Twenty-seven patients were mixed chimeras and 47 
patents were complete donor chimeras from 6 till 12 months after BMT The incidence of both 
acute and chronic GVHD was significantly higher in the group of complete donor than in the group 
of mixed chimeras (Fisher's exact test, p<0 001 and p<0 01 respectively) (Table IV) 
Table IV Relation between GVHD and mixed chimensm 
Acute GVHD 
Grade MC CDC 
0 25 24 
>l 2 23 
Chronic GVHD 
Absent 24 25 
Present 3 22 
MC= mixed chimera, CDC= complete donor chimera 
CFU-GM assay results 
We assessed routinely the number of recipient CFU-GM just prior to bone marrow infusion to 
evaluate the efficacy of the conditioning regimen to eradicate bone marrow progenitors CFU-GM 
assay results at day 0 were available in 45 out of 49, 56 out of 65 and in all 30 patients treated 
with conditioning regimen А, В and С respectively Data of the remaining patients are lacking due 
to technical reasons Table V gives the results of the CFU-GM assay at day 0 for each of the 
conditioning regimens Only a minonty of the patients appeared to have residual CFU-GM, 
irrespective of the conditioning regimen used (χ2 test P=0 4) When patients transplanted for AML, 
ALL and CML were analyzed according to disease category no significant influence of the 
conditioning regimen on the result of the CFU-GM assay was demonstrable Thirty-five out of 131 
patients with a result of the CFU-GM assay at day 0 relapsed Ten out of these 35 patients had 
demonstrable CFU-GM at day 0, which was not significantly different from the 21 out of 96 
non-relapsed patients with a positive result of the CFU-GM assay 
p<0 001 
p<0 01 
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Table V. Results of the CFU-GM assay at day 0 
CFU-GM 
Conditioning regimen 
A B C 
Negative, η (%) 
Positive, η (%) 
No of clusters + colonies 
median/range' 
35 (78) 
10 (22) 
3/1-21 
45 (80) 
11(20) 
2/1-15 
20 (67) 
10(33) 
2/1-59 
* In patients with positive CFU-GM. 
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Fig 2. Probability of relapse in good nsk patients per conditioning regimen. 
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Relapse in good risk patients 
In order to compare the probability of relapse between the three different regimens only patients 
transplanted for AML and ALL in CR1 and CML in chronic phase were included. The numbers 
of these so-called good risk patients were 32, 43 and 12 for regimens А, В and С The time to 
relapse and the follow up for the patients who did not relapse are given in Table I. For CML 
patients cytogenetic relapse was not considered as a relapse. Although the probability of relapse 
was decreased in regimen В compared to regimen A (18 versus 43%), this difference was not 
significant (p=0.07). Because of the short median follow up and the small number of évaluable 
patients no statements can be made about probability of relapse in group С yet (Figure 2). 
Discussion 
Several investigators have studied mixed chimerism after BMT with T-cell depleted marrow 
grafts from a HLA identical sibling. Techniques used were cytogenetic analysis and analysis of 
restriction fragment length polymorphisms of peripheral blood and bone marrow, mixed 
agglutination for the red cell lineage, immunoglobulin allotyping for В lymphocytes and more 
recently in situ hybridization. Mixed chimerism could be detected in all cell lineages. Combining 
the results of the different techniques the authors found incidences of mixed chimerism varying 
from 51 to 100%. 1 2 · 1 3 , 1 5 1 6 2 8 Patients transplanted in our center with marrow grafts depleted of 
lymphocytes by counterflow centrifugation showed an incidence of mixed chimerism of 6 7 % at 
6 months after BMT.14 This high incidence was explained by the use of a very sensitive fluorescent 
microsphere assay to detect recipient erythrocytes. Studying mixed erythrocyte chimerism with 
the microsphere method we found circulating recipient red cells in 59 to 7 1 % of the patients from 
6 to 24 months after BMT in contrast to the 36 and 44% found by Schouten et a l 1 3 and Roy et 
a l , 6 using agglutination techniques.24 
In the present study of mixed erythrocyte chimerism we observed a significant influence of the 
conditioning regimen on the incidence of mixed chimerism from 6 to 24 months after BMT. 
Intensification of the pretransplant conditioning by adding anthracyclines and increasing the dose 
rate of TBI caused a decrease of mixed red cell chimerism from 73 to 33% at 6 months after BMT. 
Toxic effects of the anthracyclines (severe mucositis and prolongation of the neutropenic period 
by one week compared to regimen A ) M were the reasons for replacing this regimen. Instead, 
intensification of the conditioning regimen was achieved by enhancement of the total TBI dose 
to 12 Gy. This resulted in a 20% incidence of mixed erythrocyte chimerism at 6 months after BMT. 
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Petz et a l 1 7 observed a lower incidence of mixed chimensm in patients treated with 13 2 Gy 
fractionated TBI compared with treatment with 10 Gy single dose TBI This difference was not 
significantly different Companng mixed chimeras with complete donor chimeras, Frassoni et al1 9 
found that the first had received a significantly lower dose of TBI than the latter 
An interesting question is the relation between the presence of mixed erythrocyte chimensm 
and relapse In this study CML patients who never had detectable Ph chromosome positive cells 
in the bone marrow at б months or later after BfvTT, were either complete donor chimeras or stable 
mixed chimeras with very low (< 0 5%) percentages of recipient red cells High (>10%) or 
increasing percentages of recipient erythrocytes indicated cytogenetic relapse, which was also 
observed by Frassoni et a l 1 S The involvement of the erythroid lineage in CML patients can be 
explained by the fact that the ongin of the malignant clone in CML is at the pluripotent stem cell 
level The appearance of Ph chromosome positive cells was never transient in our patients in 
contrast to observations by other authors 1 9 3 0 In six out of 10 patients with cytogenetic relapse 
there was evidence of hematological relapse during follow up 
Although in the majority (29 out of 33) of patients transplanted for acute leukemia and remaining 
in complete remission, either no or low (<1%) percentages of host erythrocytes were detectable 
during follow up, four patients were observed with a different pattern despite repeatedly high 
(5-20%) or increasing percentages of autologous erythrocytes no signs of relapse could be 
detected Other studies confirm that mixed chimensm, even with predominantly host red cells 
does not necessanly indicate relapse in patents transplanted for acute leukemia1731 Like Frassoni 
et al 1 9 we also observed patents transplanted for acute leukemia without demonstrable recipient 
red cells at the time of relapse Whether this has to be attnbuted to suppressed normal host 
erythropoiesis or a clonal expansion of a more committed stem cell not involving the erythroid 
lineage, remains unclear 
The incidence of senous GVHD > II was too low to permit an analysis of patients with grade 
II or more acute GVHD We found a significant influence of the conditioning regimen on the 
incidence of acute GVHD grade I or more being 15, 29 and 77% for conditioning regimen A, В 
and С respectively As descnbed by Truitt and Atasoylu E i n a mouse BMT model, more host T-
cells are eliminated by increasing the TBI dose This was associated with increased donor T-cell 
chimensm and a higher incidence of GVHD Companng two conditioning regimens with a TBI dose 
of 12 and 15 75 Gy, Clift et a l 3 3 observed a significantly higher probability of developing grade 
II or more acute GVHD in the patients receiving the highest TBI dose In that study however, it 
was not clear whether the higher dose of TBI predisposed to GVHD or whether GVHD was seen 
more frequently because fewer patients in the 15 75 Gy group received optimal treatment with 
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MTX and CsA. The significant impact of age on the occurrence of acute GVHD was also observed 
by Zwaan et al M. Gale et al*, studying risk factors for acute GVHD, found no significant influence 
of age on the incidence of acute GVHD. Although patients in group В received significantly more 
T-cells in the graft, the absolute numbers were still very low compared with unseparated marrow 
grafts. This might be an explanation for the lack of a significant influence of the number of T-cells 
on the incidence of acute GVHD and mixed chimerism in this study. 
No significant influence of the conditioning regimen on the occurrence of chronic GVHD could 
be observed in our study with an incidence of chronic GVHD of 23, 43 and 46% for regimen A, 
' В and С respectively. This is in contrast to the linear correlation between total dose of TBI and 
incidence of chronic GVHD found by Frassoni et al.36 We did find a significantly higher incidence 
of both acute and chronic GVHD in complete donor chimeras compared with mixed chimeras, 
suggesting a role for GVHD in eliminating residual host cells. These results are in line with the 
data of Frassoni et al.19 The percentage of patients with residual host CFU-GM just prior to bone 
marrow infusion varied from 20 to 33% amongst the three different regimens. Despite this the 
incidence of mixed chimerism decreased with intensification of the regimen. This may imply that 
GVHD which occurred more frequently after the intensified regimens is responsible for the 
decreased incidence of mixed chimerism rather than the intensity of the regimen. Future strategies 
should study the possibilities of ¡mmunomodulation rather than a mere intensification of the 
conditioning. Kolb et al37 were able to reinduce complete hematological and cytogenetic remission 
in three CML patients, who relapsed after BMT, by transfusion of buffy coat from the original 
marrow donor. Because of the rather high relapse rate in CML patients, this kind of adoptive 
immunotherapy might be considered at some time point after BMT. 
As pointed out by Apperley et al30 and Horowitz et al11 there is a significant influence of the 
occurrence of acute and/or chronic GVHD on the rate of leukemic relapse in patients receiving 
T-cell depleted marrow grafts. Comparing patients treated with regimen A and В we observed 
an increased Incidence of chronic GVHD (p=0.048) and a trend to a lower relapse rate in the latter 
group. Intensification of the pretransplant conditioning could also have contributed to this trend. 
The incidence of acute GVHD increased in patients treated with regimen C, but GVHD was of 
mild (grade I) severity in the majority of these patients. In view of the increased incidence of acute 
GVHD and in view of the postulated higher antileukemic activity of regimen C,33 we anticipate 
a lower relapse rate. Additional follow up and more patients are needed to assess our 
expectations. 
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Donor leukocyte infusions for chronic myeloid leukemia 
Summary 
Purpose 
Treatment options for patients with chronic myeloid leukemia (CML) who relapse after allogeneic 
bone marrow transplantation (BMT) are limited Treatment with lymphocytes from the onginal 
marrow donor and the influence on the malignant clone was studied in these patients 
Patients and methods 
Seven patients with CML that had relapsed after BMT with T-cell depleted grafts were treated 
Six patients received leukocyte infusions from the onginal marrow donor One patient received 
a second BMT with unseparated marrow from the same sibling donor Chimensm was studied 
using erythrocyte and cytogenetic markers Residual leukemic cells were monitored by cytogenetic 
analysis of the Philadelphia (Ph) chromosome and by polymerase chain reaction (PCR) of the 
Breakpoint Cluster Region/Abelson (BCR-ABL) fusion gen 
Response 
In five patients with hematologic relapse the Ph chromosome disappeared 1 to 3 months after 
the leukocyte infusions Cytogenetic analysis and in situ hybridization (ISH) showed only donor 
cells dunng further follow up Four of five patients became negative for the BCR-ABL translocation 
by PCR Graft-versus-host desease (GVHD) always preceded response and was severe in two 
patients One patient with cytogenetic relapse showed no response after leukocyte infusions 
GVHD after second BMT was of moderate seventy One year after second BMT, PCR for the 
BCR-ABL translocation was negative 
Conclusion 
Infusion of donor leukocytes is an effective treatment with a low mortality in patients with CML 
relapsed after BMT with a T-cell depleted graft Longer follow up and more patients will be needed 
to know whether cure will be permanent 
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Introduction 
CML is a fatal malignant stem cell disorder characterized cytogenetically by the Ph chromo-
some a specific translocation of the Abelson (ABL) oncogene on chromosome 9 to the Breakpoint 
Cluster Region (BCR) on chromosome 22 
Allogeneic BMT is the only curative option for CML ' Relapse rates in patients transplanted 
for CML in first chronic phase vary from 10% to 20% in recipients of a non T-cell depleted graft 
Higher relapse rates up to 50% to 60% have been observed when T-cell depletion is applied to 
decrease the incidence of GVHD or when transplantation has been performed in more advanced 
stages ' 2 Only a minority of patients with relapse CML after BMT achieve a cytogenetic remission 
after treatment with interferon alfa ( INFa)3 Other treatment possibilities are second BMT45 or, 
as recently descnbed, infusion of leukocytes from the onginal marrow donorM 
This report descnbes the study of seven CML patients who relapsed after BMT with T-cell 
depleted marrow Six of them were treated with donor leukocyte infusions and one received a 
second BMT using unmanipulated marrow from the same donor We report on hematologic 
response and GVHD Mixed chimensm was studied using erythrocyte and cytogenetic markers 
Monitoring of residual leukemic cells was performed by cytogenetic analysis of the Ph chromosome 
and by PCR of the BCR-ABL fusion molecules 
Patients and methods 
Patients 
Seven CML patents who relapsed within 6 to 36 months after BMT were treated in an attempt 
to achieve a second complete remission Patient charactenstics are listed in Table I 
At the time of BMT, all patients were in first chronic phase of CML except for patient no 91, 
who was in accelerated phase Patient no 91 received a marrow graft from a one A-locus 
mismatched, mixed lymphocyte culture (MLC)-negative sibling, all other donors were HLA A/B/ 
Or identical, MLC-negative siblings The conditioning regimen consisted of cyclophosphamide 
and total body irradiation (TBI) as previously descnbed9 All patients received donor marrow 
depleted of 98% of lymphocytes by density gradient centnfugation followed by counterflow 
centnfugation 10 Cyclosponn A (CsA) was used as immunoprophylaxis posttransplant in all 
patients9 Data on the occurrence of GVHD after BMT are listed in Table I 
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Table I. Patient characteristics 
Patient 
No. 
64 
132 
125 
51 
91 
166 
68 
* Month-year 
Date of 
diagnosis* 
11-85 
5-89 
8-88 
8-85 
2-83 
7-90 
3-84 
"Years 
Date of 
BMT* 
12-86 
9-89 
6-89 
5-86 
3-88 
10-90 
2-87 
Age at 
BMT** 
31 
27 
33 
46 
25 
47 
35 
Se) 
Patent 
Male 
Male 
Male 
Male 
Female 
Male 
Female 
t 
Donor 
Male 
Female 
Female 
Male 
Male 
Male 
Female 
GVHD 
Acute 
Skin, grade I 
Skin, grade I 
Skin, grade II 
Chronic 
Mild 
— 
— 
Moderate 
— 
Mild 
Treatment of relapse 
Cytogenetic analysis of bone marrow was performed at 6 and 12 months after BMT and yearly 
thereafter. In five patients (no. 64, 125, 51, 91 and 68), no Ph chromosome positive cells could 
be demonstrated at one to three time points of analysis after BMT. Subsequently, they became 
Ph chromosome positive and developed hematologic relapse of CML. Patient no. 132 had Ph 
chromosome positive cells at 6 and 12 months after BMT with signs of hematologic relapse at 
the latter time point. Patient no. 166 was Ph chromosome positive at 6 months after BMT, but 
has shown no signs of hematologic relapse thereafter (Table II). 
Table II. Data on relapse and infusion of mononuclear cells 
Patent 
No. 
64 
132 
125 
51 
91 
166 
68 
Time to relapse* 
Cytogenetic 
12 
6 
24 
12 
36 
6 
24 
Hematologic 
24 
12 
24 
12 
36 
— 
24 
Treatment before 
infusion 
Busulfan 
IFNa 
— 
Busulfan 
IFNy 
IFNa 
Busulfan 
IFNa 
Busulfan 
IFNa 
Time to 
infusion* 
51 
19 
25 
63 
65 
41 
13 
17 
36 
Nucleated cells 
(xlO'/kg) 
0.34 
0.34 
1.48 
1.3 
2.38 
1.65 
1.8 
3.4 
2.7 
Lymphocytes 
(x10'/kg) 
0.26 
0.25 
1.1 
0.96 
1.78 
1.1 
1.27 
2 5 
0.38 
No of 
infusions 
4 
4 
2 
2 
4 
2 
3 
8 
Second BMT 
* Months after BMT 
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Relapse of CML was treated with different drugs (Table II). Patient no. 64 received busulfan 
in a dose of 2 mg/day, 5 days a week during 30 months. Patient no. 132 was treated with INFa 
5x106 U, three times a week for 6 months. Patient no. 51 initially received busulfan 4 mg/day, 5 
days a week for 6 months and subsequently interferon gamma (INFy) 0.5 mg/day, three times 
a week for 12 months. Treatment consisted of INFa 3x106 U/day during the last 2 years before 
leukocyte infusions. Patient no. 91 was treated with busulfan 6 mg/day for 1 month. Patient no. 
166 received INFa 3x106 U/day, 3 days a week for 6 months. However, 1 week before infusion 
of donor leukocytes, drug treatment was discontinued in all patients. All patients had Ph chromo­
some positive cells in the bone marrow immediately before the start of the leukocyte infusions. 
Nucleated cells from the donor were obtained by leukapheresis using a blood cell separator 
the Baxter CS 3000 (Deerfield II) in patients no. 64 and 132, and the Fresenius AS 104 (Oberursel, 
Germany) in the other four patients. Each donor underwent two to eight leukapheresis procedures 
with a time interval between the sessions of 2 to 5 days. Nucleated cells were administered to 
the patient within 3 hours after completion of the procedure. Two patients (no 51 and 166) were 
given 2 courses of leukocytes with an interval between the first and second course of 2 and 4 
months, respectively. The total number of infused nucleated cells and lymphocytes, as well as 
the frequency of infusions, is listed in Table II. In all donors, the infused nucleated cells consisted 
mainly of lymphocytes (70% to 85%) and monocytes (10% to 15%). Immunophenotypic analysis 
of the infused cells was performed in three donors (Table III). CD3, CD4, and CD8 were used 
as markers forT-lymphocytes, T-helper cells, and T-suppressor cells, respectively. Natural killer 
cells were characterized by CD56 positivity or CD3 negativity/CD16 positivity. CD19 was used 
as a B-lymphocyte тагЧег. The percentage of T-lymphocytes in the infused cells varied from 69% 
to 75% among different donors. 
Table III. Immunophenotypic analysis of infused nucleated cells (%) 
Patient No. CD3* CD4* CD8' CD3.CD16* CD56* CD19' 
125 75 47 38 11 17 10 
51* 72 47 28 9 26 14 
166t 69 55 21 13 18 10 
166* 75 58 21 10 13 11 
* Second course of transfusion, 
t First course of transfusion. 
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Patient no 68 relapsed 2 years after BMT Treatment consisted of busulfan 4 mg/day for 4 
months, followed by INFa 5x10e U/day for 9 months She received a second unseparated marrow 
graft from the same donor 36 months after the first BMT The conditioning regimen consisted of 
standard dose busulfan and cyclophosphamide 11 
All patients who were treated with donor leukocyte infusions or second BMT for CML that 
relapsed after BMT are included in this analysis 
Erythrocyte markers 
Complete RBC phenotyping of patient and donor was performed before BMT Antigenic 
differences of patent and donor were used as marker antigens Marker antigens in this study were 
A1, A2, В, e, E, F/, Fy", Jkb, Μ, N and S Only erythrocytes lacking these markers were transfused 
after BMT 12 Measurement of host and donor erythrocyte populations was performed by a 
fluorescent microsphere method 13 The sensitivity of this assay is one positive cell per 10000 
negative cells (0 01%) 
Cytogenetic analysis 
Bone marrow cells were harvested directly and/or after a 24-hour culture in RPM11640 medium 
without mitogens, and processed for cytogenetic analysis using standard techniques, including 
GTG banding As a standard, 32 cells were karyotyped and, as a consequence, monitored for 
the presence of the Ph chromosome In case of a poor mitotic yield, at least 20 cells were 
karyotyped (range, 20 to 35, mean, 30, allowing the detection of a level of 10% mosaicism with 
a 95% confidence level) " If patient and donor were of different sex, additional identification of 
the Y chromosome was performed using QFQ banding In situ hybridization (ISH), using a 
combination of chromosome X- and Y-specific probes (p Bam X5 and DY 21) was performed on 
400 bone marrow cells in interphase to discriminate between patient and donor15 A signal that 
discriminated one to five cells out of 400 was considered background In case of equal sex, 
discrimination of patient and donor cells could be made using a chromosome 9 (patients no 64 
and 68) or a chromosome 1 (patient no 51) heterochromatin polymorphism in conjunction with 
C-bandmg 16 In patient no 166 discrimination of patient and donor cells could not be made by 
cytogenetic analysis 
BCR-ABL breakpoint molecules 
To detect BCR-ABL breakpoint molecules in bone marrow, RNA was isolated from 106 bone 
marrow-denved nucleated cells in a modification of the method reported by Chomczynski and 
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Sacchi17 One tenth of the RNA amount was used in a reverse transcriptase (RT) reaction using 
A21 pnmer (antisense, position 686 to 66818) In a final volume of 20 μΙ, 10 pmoles pnmer, 200 
U Moloney Murine Leukemia virus (MoMufv) RT (Gibco/BRL, Breda, The Netherlands), 12 5 nmol 
deoxynucleoside tnphosphate (dNTP), and 20 U RNAsm (RNASE inhibitor trademark of Promega, 
Madison, Wl) were incubated for 10 minutes at 20°C, followed by a 45 minute incubation at 42°C 
and denatured at 95°C for 10 minutes After this, two senes of PCR were performed In the first 
senes, pnmers B11 (nucleotide 360 to 38218) and A21 were used in a 30 cycle PCR 30 seconds 
at 95°C, 30 seconds at 72°C, 90 seconds at 58°C For this, 1 5 U Taq polymerase (Gibco/BRL), 
appropriate PCR buffer, and 10 pmol B11 pnmer were added to the RT mixture up to a 80 μΙ 
reaction volume In the second senes, B12 (nucleotide 387 to 4081β) and A22 (antisense, position 
642 to 6191β) pnmer were used in a 35 cycle PCR Reaction conditions were as in first senes, 
an additional 30 pmol of both pnmers, 1 5 U Taq polymerase, 12 5 nmol dNTP, and PCR buffer 
were added up to a 100 μΙ. reaction volume 
To assess the quality of each RNA sample, we used one tenth of the isolation in a RT reaction 
followed by PCR on ß2-microglobulm RNA This reaction was checked by agarose gel electropho-
resis Dunng RNA isolation, RNA from 10s Jurkat cells was isolated in parallel to check for 
contamination To prevent contaminations, all solutions used for RT-PCR were aliquoted and 
checked for contamination Aerosole-resistant pipette tips were used RNA isolations, PCR 
preparations, and analysis of PCR products were physically separated In each PCR, both positive 
and negative controls were used 
A15% aliquot of the PCR products was analyzed by hybridization after Southern transfer using 
a radioactively labelled c-ABL oligonucleotide recognizing the 5' part of exon 2 of the c-ABL gene 
Bone marrow samples were regarded to be positive for the BCR-ABL breakpoint molecules when 
a hybndization signal was visible after exposure of the filters, whereas negative controls were 
negative after exposure of the film and the ß2-microglobulin reaction was positive on agarose gel 
Samples were regarded to be negative when no signal was visible on the autoradiogram after 
two rounds of PCR, whereas positive controls and the ß2-microglobuhn reaction were positive after 
one round of PCR This way, one leukemic cell amongst at least 10s normal cells could be 
detected 1Э 
RESULTS 
Hematologic response 
Two patients developed severe hypoplasia after infusion of donor leukocytes Patient no 64 
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had no detectable donor cells prior to the infusions He became pancytopenic 5 weeks after the 
leukocyte infusions simultaneously to the onset of GVHD The granulocyte count recovered to 
greater than 0 5x109 5 months after infusion and the platelet recovery was only partial (20x109 
without platelet support) at the time of this report The erythrocyte transfusion requirement has 
gradually decreased to 2 U per month The second patent (no 91) developed severe neutropenia 
2 weeks after the leukocyte transfusions and severe thrombocytopenia 2 weeks later in association 
with severe GVHD The hypoplasia recovered after treatment of GVHD with corticosteroids The 
remaining four patients treated with donor leukocytes did not develop clinically significant 
cytopenia The patent transplanted with unseparated donor marrow after bone marrow ablative 
therapy was granulocytopenic for 13 days, while platelet recovery to more than 50x109 occurred 
after 2 months after BMT 
Graft-versus-host disease 
All patients who responded to the donor leukocyte infusions developed GVHD The clinical 
picture of GVHD in these patients was more or less identical to that of chronic GVHD, which can 
be observed in recipients of donor marrow 3 months after BMT with or without a preceding phase 
of acute GVHD Clinical manifestations of GVHD in skin, liver, and gut, graded according to the 
entena published by Glucksberg et a l я are listed in Table IV GVHD was extensive in two patents 
(no 64 and 91) It consisted of a generalized exanthema, severe oromucositis, and oesophagitis 
and liver function abnormalities Both patients showed a partial response to corticosteroids only 
and a satisfactory response after addition of CsA However, patent no 91 died suddenly 6 months 
after leukocyte infusions from sepsis onginating from a fulminant cellulitis of her left leg 
Table IV Clinical manifestation of GVHD 
Patent 
No 
64 
132 
125 
51 
91 
166 
68 
Skin 
2 
2 
1 
2 
3 
— 
2 
Grade 
Liver 
2 
3 
3 
1 
2 
— 
— 
Gut 
2 
-
-
— 
1 
— 
-
One patient (no 166) did not respond to the donor leukocyte infusions The remaining four 
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patients (including the patient with second BMT) developed clinical signs of GVHD. GVHD was 
limited to skin and liver in three patients and responded to treatment with corticosteroids only 
The fourth patient (no. 51) did not respond to the first course of leukocyte infusions, but he 
developed exanthema, liver function abnormalities, and thrombocytopenia with a nadir of 28x109/l 
after the second course. He was treated with corticosteroids and CsA. Cytomegalovirus 
pneumonitis was diagnosed 10 weeks after the second transfusion period. The pneumonitis 
responded favourably to gancyclovir. 
Erythrocyte markers and erythrocyte transfusions 
Recipient erythrocyte markers were available in six of seven patients (Table V). Recipient 
erythrocytes disappeared completely in three patients. In patient no. 91, the rapid decrease in 
recipient erythrocytes between 1 week and 1 month after the leukocyte infusions could be 
attributed to hemolysis. Hemolysis was caused by a donor-derived antibody in a setting of minor 
ABO incompatibility of patient and donor (patient A, donor O).21 The percentage of recipient 
erythrocytes decreased to very low levels (0.02%) in patient no. 64. In patient no. 51, who 
responded to the second course of infusions, the recipient erythrocyte level is still decreasing. 
Patient no. 166 showed no response. Donor erythrocyte markers were available in five patients. 
A complete restoration was observed in three patients. The percentage of donor erythrocytes Is 
slowly increasing in patient no. 64, who is still suffering from moderate GVHD. The fifth patient 
showed a persistent absence of donor erythropoiesis, probably caused by a major ABO 
incompatibility of donor and patient (patient O, donor A2).22 
In situ hybridization and cytogenetic markers 
Three patients had donors of opposite sex. All three patients had no recipient cells detectable 
using ISH 6 months after leukocyte infusions (Table V). Cytogenetic recipient markers were 
present in six patients. In all six patients, recipient cells were no longer detectable at periods 
varying from 1 to 6 months after the leukocyte transfusions onward. 
Philadelphia chromosome and BCR-ABL breakpoint molecules 
Ph chromosome was present in all patients before treatment. It could no longer be detected 
in the 25 to 32 metaphases analysed in all six responders from 1 to 6 months after treatment 
onward. Patient no. 166 received a second course of infusions. Follow up in this patient is short 
(5 months), but there were no signs of cytogenetic response 3 months after leukocyte infusions. 
The BCR-ABL translocation could be detected in all 6 patients who were treated with donor 
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leukocytes. Four of six patients became negative in PCR at 3 to 12 months after leukocyte 
infusions. Patient no 51, who responded cytogenetically to the second course of infusions, still 
has BCR-ABL breakpoints demonstrable 6 months after the second treatment. Patient no. 166 
did not show a molecular response (Table V). Patient no. 6Θ was PCR negative 12 months after 
second BMT. 
Median follow up after leukocyte infusions is 12 months (range, 5 to 19 months). 
Table V. Analysis of mixed chimerism and residual leukemic cells 
Patent 
No 
64 
132 
125 
51 
91 
166 
66 
Time related 
to infusion 
before 
3 months 
6 months 
12 months 
before 
2 months 
3 months 
6 months 
12 months 
before 
1 week 
1 month 
3 months 
6 months 
12 months 
before 
1 week 
1 month 
1 week§ 
1 month§ 
3 months§ 
6 months§ 
before 
1 week 
1 month 
3 months 
6 months 
before 
1 week 
1 month 
3 months 
1 monthf 
3 months§ 
6 months 
12 months 
Erythrocyte 
%P 
88 6 
48 4 
0 05 
0 02 
48 7 
1.1 
0 
0 
NA 
NA 
NA 
NA 
NA 
NA 
100 
100 
9 6 7 
100 
100 
27 1 
0 03 
82 3 
92 6 
112 
0 01 
0 
87 5 
100 
95 
9 6 7 
81 
88 
NA 
0 
%D 
0 
0 37 
0 47 
30 
NA 
NA 
NA 
NA 
88 6 
75 4 
94 7 
90 5 
99 2 
89 
0 
0 
0 013 
0 
0 
0 
0 
0 1 8 
174 
13 
28 5 
951 
NA 
NA 
NA 
NA 
NA 
NA 
93 4 
100 
Cytogenetic analysis 
Ρ D 
20 (Ph*) 
0 
0 
0 
23 (Ph*) 
0 
0 
0 
0 
12 (Ph*) 
7 (Ph*) 
8 (Ph*) 
0 
0 
0 
27 (Ph*) 
31 (Ph*) 
24 (Ph*) 
26 (Ph*) 
21 (Ph*) 
0 
0 
32 (Ph*) 
31 (Ph*) 
0 
0 
0 
4Ph+/32¥ 
2Ph+/20 
6Ph+/20 
14Ph+/20 
15Ph+/20 
12Ph+/20 
0 
0 
0* 
32 
32 
32 
9 
32 
32 
32 
32 
20 
25 
27 
32 
32 
20 
5fl 
1 
8 
6 
4 
32 
32 
0 
1 
32 
32 
32 
25* 
30 
Ρ 
0 
0 
1 
75 
92 
5 
0 
2 
387 
0 
1 
1 
ISH 
D 
400 
400 
399t 
325 
308 
395t 
400 
398t 
13 
400 
399f 
399Î 
BCR-ABL 
Translocation 
Ь2а2(+) 
Ь2а2(+) 
Ь2а2(+) 
Ь2а2 (-) 
Ь3а2(+) 
Ь3а2(+) 
Ь3а2(-)* 
Ь3а2 (-) 
Ь3а2(+) 
Ь3а2(+) 
Ь3а2(-» 
Ь3а2(-) 
Ь3а2(-) 
Ь2а2(+) 
Ь2а2(+) 
Ь2а2(+) 
Ь2а2(+) 
Ь2а2(+) 
Ь2а2(+) 
Ь2а2(+) 
Ь2а2(+) 
Ь2а2(+) 
Ь2а2(+) 
Ь2а2(-) 
Ь2а2(-) 
Ь2а2(+) 
Ь2а2(+) 
Ь2а2(+) 
Ь2а2(+) 
Ь2а2(+) 
Ь2а2(+) 
(-) 
Abbreviations Ρ, patent; D, donor; NA not available, b, exon of BCR gene, a2, second exon of ABL gene 
* Discrimination of patent and donor by vanance of chromosome 9 t One of 5 discnmmating cells are considered 
background t First test weakly positive, repeat test negative § After second course of transfusion *| Discnminaton 
of patent and donor by vanance of chromosome 1 ¥ No discnminaton of patent and donor by cytogenetic analysis 
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DISCUSSION 
Relapse rates of 50% and higher have been observed in CML patients after BMT with T-cell 
depleted grafts compared to 10% to 20% in CML patients transplanted with unseparated marrow1 
Part of the reduced antileukemic activity of T-cell depleted grafts can be explained by a lower 
incidence of GVHD An additional antileukemic effect mediated by T-lymphocytes independent 
of GVHD has been suggested to be important for permanent cure of CML patients2 A seceond 
BMT with unseparated marrow may achieve long term disease-free survival in patients with 
relapsed CML, reflecting the antileukemic effect of T-cells in the graft45 This is associated with 
a high procedure-related mortality *5 In this study one patient received a second BMT with 
unseparated marrow from the same donor 3 years after the first BMT Acute and chronic GVHD 
after second BMT were of moderate seventy and responded well to treatment with corticosteroids 
only Twenty months after second BMT, she is in hematologic remission with no detectable 
recipient cells PCR of the BCR-ABL breakpoint molecules was negative 12 months after second 
BMT 
Recently, two case reports have been published on infusion of donor buffy coat in a small 
number of patients with CML who had relapsed after BMT M Kolb et a l 6 induced cytogenetic 
remission in three patients with hematologic relapse by treatment with INFa followed by donor 
leukocyte infusions Two of them developed GVHD Cullis et a l 7 desenbed two patients with 
cytogenetic relapse after BMT Both of them became Ph chromosome negative and subsequently 
BCR-ABL breakpoint molecule negative after donor leukocyte infusions Both patients developed 
GVHD Drobyski et al8 desenbe one patient with relapsed CML after a second BMT who achieved 
hematologic, cytogenetic, and molecular remission after leukocyte infusions In this study five of 
six patients became Ph chromosome negative after donor transfusions In four of five patients, 
BCR-ABL breakpoint molecules were no longer detectable dunng further follow up Besides 
erythrocyte markers, cytogenetic analysis, and ISH, we used PCR on vanable number of tandem 
repeats (VNTR) to evaluate chimensm a In the responding patents, recipient cells were no longer 
detectable using cytogenetic analysis and ISH Recipient erythrocytes disappeared in two and 
decreased markedly in two patents The results of VNTR were in accordance with the outcome 
of the other assays (data not shown) 
Residual leukemic cells can be detected in CML patients by cytogenetic analysis of the Ph 
chromosome and by PCR to detect the BCR-ABL breakpoint translocation The latter assay is 
approximately 1000 times more sensitive than cytogenetic analysis This explains the fame 
difference between attaining a cytogenetc remission and a BCR-ABL breakpoint molecule negative 
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status 
In a study on the role of PCR in predicting relapse after BMT for CML, Hughes et a l 2 4 found 
that PCR negativity post-BMT was predictive of a low risk of relapse They suggested that PCR 
positjvity up to 6 months after BMT had no adverse prognostic significance, in contrast to PCR 
positivity after 6 months Extrapolating these findings, we may expect a low relapse rate in five 
patients in this study who became negative in the PCR of the BCR-ABL fusion gene We recently 
described a relatori between the percentage of recipient RBCs and the cytogenetic status in CML 
patients after BMT й No or low percentages (<0 5%) of recipient RBCs at 6 months or later after 
BMT were observed in patients with continuous cytogenetic remission In contrast, high (>10%) 
or increasing percentages of recipient erythrocytes indicated cytogenetic relapse Further follow 
up will be necessary to prove whether this will also apply to patients after donor leukocyte 
transfusions 
Cytogenetic response was always preceded by manifestations of GVHD in our patients The 
clinical picture resembled that of chronic GVHD observed 3 months or later after BMT of a first 
marrow graft The number of lymphocytes transfused was equal to the usual number of 
lymphocytes in non-T-cell-depleted marrow grafts in two patients (no 64, 132), but three to 10 
times higher in the remaining patients We observed no relation between the seventy of GVHD 
and the number of transfused lymphocytes GVHD was of moderate seventy and responded well 
to treatment in three patients (no 132, 125, and 51) GVHD was more severe in patient no 64 
and attributed to death in patient no 91 Two patients became pancytopenic after donor leukocyte 
transfusions, which was associatiated with GVHD with partial recovery in patient no 64 who had 
no detectable donor cells prior to the infusions Patient no 91 showed complete recovery after 
corticosteroid treatment This patient died from sepsis 6 months after the leukocyte infusions 
The mortality rate of this treatment approach appeared to be low, with a high response rate For 
this reason, donor lymphocyte infusions seem to be the treatment of choice for CML relapsed 
after BMT The exact number of lymphocytes required for therapeutic effect remains to be 
determined Patient no 51 is interesting for this point He responded to a second treatment with 
twice as many lymphocytes compared with the first treatment 
We conclude that infusion of donor leukocytes is an effective treatment in CML patients with 
relapse after BMT with a T-cell depleted graft This treatment is capable of inducing a BCR-ABL 
breakpoint molecule-negative status Moderate to more severe GVHD always preceded response 
in these patients Longer follow up and additional patients will be needed to know whether cure 
will be permanent It will be interesting to test the possibility of separating GVHD from 
graft-versus-leukemia effect by infusing certain subpopulations of donor lymphocytes, eg, natural-
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killer cells 
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Major ABO incompatible lymphocyte-depleted BMT 
Summary 
Forty-four out of 258 allogeneic BMT were performed across the major ABO bamer Donor 
erythrocyte repopulation could be evaluated in 30 cases Fifty-eight patients transplanted with 
an ABO compatible or minor incompatible graft served as the control group All patients received 
a marrow graft depleted of lymphocytes by counterflow centnfugation Less than 108 residual 
erythrocytes were present in the graft Cyclosponn A was used as immunoprophylaxis after 
transplantation Erythrocyte repopulation was measured using a fluorescent microsphere method 
An adapted transfusion policy was applied 
Eight out of 30 patients (27%) with major ABO incompatibility had no detectable donor 
erythrocytes 2 months after BMT Up to 3 months after BMT donor erythrocyte repopulation was 
significantly delayed in the ABO incompatible group (p^O 03) Significantly more erythrocyte 
transfusions were required in the ABO incompatible group (p<0 001) Six patients with blood group 
О (20%) developed pure red cell aplasia which resolved in 5 without therapeutic intervention In 
these six patients anfc-A antibody titers were persistently high the first 3 months after BMT This 
was in contrast with 22 patients with timely recovery of erythropoiesis in whom anti-Α and anti-B 
antibody titers showed a steady decrease after BMT 
The incidence of immunohematological complications in these patients who received a 
lymphocyte depleted major ABO incompatible graft is similar (20%) to the incidence reported in 
the literature Senous morbidity related to major ABO incompatibility did not occur 
Introduction 
Major ABO incompatibility between recipient and donor occurs in about 10-15% of HLA matched 
allogeneic bone marrow transplantations Acute hemolysis by anti-Α or anti-B antibodies of 
recipient ongin at the fame of infusion of the donor marrow can be prevented by reduction of the 
antibody titers in the recipient or by removal of erythrocytes from the graft1 s 
Studies by Bensmger et al6 and Buckner et al7 have demonstrated that major ABO incompatibility 
is no obstacle to successful outcome after BMT No increased nsk of graft rejection, graft versus 
host disease (GVHD) or mortality related to ABO incompatibility has been observed Several 
reports have descnbed delayed hemolytic anemia, delayed onset of erythropoiesis, pure red cell 
aplasia (PRCA) and increased posttransplant transfusion requirements after major ABO incorn­
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patible ΒΜΤΛ13 
In contrast to the previous studies all patients transplanted in our center received marrow grafts 
depleted of lymphocytes by elutriation. Donor erythropoiesis and transfusion requirements were 
evaluated in 30 patients who received a major ABO incompatible graft and compared to an ABO 
compatible or minor ABO incompatible control group of 58 patients. Delayed onset of 
erythropoiesis occurred in eight patients who received a major ABO incompatible graft The clinical 
course after BMT of these patients is described in more detail. The pretransplant titers and the 
posttransplant course of ABO antibodies in these patients were compared to those of the other 
22 patients transplanted with a major ABO incompatible graft. 
Subjects and methods 
Patient groups 
From 1981 to 1994, 285 allogeneic bone marrow transplantations were performed in adults. 
In 44 cases (15%) major ABO incompatibility existed between patient and donor. In 14 out of 44 
patients donor erythrocyte repopulation could not be evaluated for the following reasons; early 
transplant related mortality within one month after BMT in three, early relapse within 6 months 
after BMT in five, graft failure and autologous recovery in three and no available data in three 
patients. The remaining 30 patients were transplanted for acute myeloid leukemia (AML) (n=6), 
acute lymphoid leukemia (ALL) (n=8), chronic myeloid leukemia (CML) (n=14), severe aplastic 
anaemia (SAA) (n=1) and eosinophilic syndrome (n=1). Twenty patients with blood group О 
received either a blood group A graft (n=19) or a blood group В graft (n=1). AB marrow was trans­
planted to three patients with blood group A and one patient with blood group B. Three patients 
with blood group A received a blood group В graft and three patients with blood group В received 
a blood group A graft. 
Twenty-six donors were HLA-identical sibling donors and four donors were HLA matched 
unrelated volunteers (UPN 168, 199, 226 and 281). Conditioning regimens always included 
cyclophosphamide (Cy) in a total dose of 120 mg/kg. This was followed by total body irradiation 
(TBI) in two equal fractions with 24 h interval in a total dose of 9 or 12 Gy in 28 patients. 
Anthracyclines (daunorubicin 156 mg/nr or demethoxydaunorubicin 42 mg/nf ) were added in 
18 out of 22 patients who received TBI in a dose of 9 Gy. One patient (UPN 281) was conditioned 
with Cy, TBI (9Gy) and total lymphoid irradiation (TLI) (8Gy). Another patient was treated with 
busulfan and Cy (UPN 126). In the only patient (UPN 226) transplanted for SAA the conditioning 
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regimen consisted of Су and TLI (12Gy) Details on the conditioning regimens have been descnbed 
earlieru 1S Plasma exchange or plasma immunoadsorption to reduce anti-Α or anti-B antibody 
titers before BMT were never applied 
In the same time period, 241 ABO compatible or minor ABO incompatible transplantations were 
performed Fifty-eight patients could be used as a control group to study donor erythrocyte 
repopulation The remaining patients were considered not to be évaluable mainly because of lack 
of a donor erythrocyte marker (see below) or because they received unselected transfusions not 
taking into account the donor marker Other reasons were early transplant-related mortality, early 
relapse or graft failure Indications for transplantation were AML (n=14), ALL (n=15), CML (n=17), 
low-grade non-Hodgkin lymphoma (n=5), multiple myeloma (n=4), SAA (n=2) and myeloproliferative 
syndrome (n=1) Fifty-four donors were genotypically HLA-identical sibling donors and four donors 
were one locus mismatched siblings The conditioning regimens always included Cy (120 mg/kg) 
Except for one patient who was treated with TLI, all patients received TBI in a total dose of 9 or 
12 Gy Anthracyclmes were added in 35 out of 39 patients treated with TBI in a dose of 9 Gy 
Both in the study and in the control group all marrow grafts were depleted of lymphocytes by 
density gradient centnfugation followed by counterflow centnfugation 16 Less than 10e residual 
erythrocytes were present in the marrow graft Cyclosponn A (CsA) was used as immunc-
prophylaxis posttransplant in all patients in a schedule, as previously descnbed 17 
Erythrocyte markers 
Analysis of patient and donor erythrocyte populations the first months after BMT required an 
adapted transfusion policy1β 19 Before BMT, preferentially before any transfusions were given, 
a sample for complete red cell phenotypmg was drawn from the patient After phenotyping of the 
donor, marker antigens, ι e antigens present in the donor and absent in the recipient and vice 
versa, were determined In case of major ABO incompatibility the A or В antigen was used as 
a donor marker In the control group donor marker antigens were C, c, D, Ε, Κ, M, N, S, s, Fy3, 
Fy", Jka, Jk" and Kpa Erythrocyte transfusions of blood group О lacking the marker antigens were 
administered to all patients in both groups 
Measurement of host and donor populations was performed by a fluorescent microsphere 
method The sensitivity of this assay is one positive cell per 10000 negative cells (0 0 1 % ) ж Donor 
erythrocyte repopulation was studied at 0 5, 1,2, 3, and 6 months after BMT 
Anti-Α and anti-B antibodies 
Anti-Α and anb-B agglutinin (IgM) titers were determined by incubating a 3% standard A and 
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В erythrocyte suspension in saline with 2-fold serial dilutions of patient serum at 37QC for 45 min 
followed by centrifugation and scoring for macroscopic agglutination. Anti-Α and anti-B IgG titers 
were measured by pretreating the patient serum with dithiotreitol at 37°C for 45 min followed by 
indirect antiglobulin testing with anti IgG serum and scoring for macroscopic agglutination. 
Antibody titers were determined before and at least 0.5, 1,2,3, and 6 months after BMT. 
Statistical analysis 
The Fisher's exact test was used to compare clinical variables between groups. The Kruskal-
Wallis test was applied to compare percentages of donor erythrocytes at different time points after 
BMT. Within the study group antibody titers were compared using the Mann-Whitney U test. 
Results 
Recovery of erythropoiesis in the study and control group 
Because of reasons mentioned earlier it was not possible to form a fully matched control group 
based on matching for indication for BMT, conditioning regimen, age and acute GVHD. Table I 
shows the comparison of clinical variables between the two groups. No significant differences 
could be found. 
Table II shows the means and standard deviations of percentages of donor erythrocytes at 
various time points after BMT. Significant delay in donor erythrocyte repopulation in the ABO 
incompatible patient group compared to the control group could be demonstrated up to 3 months 
after BMT. The difference between the two groups was no longer significant at 6 months after 
BMT. 
To demonstrate delayed donor erythrocyte repopulation in the major ABO incompatible group 
we compared the relative number of patients without detectable donor erythrocytes (i.e. <0.01 %) 
between both groups at various time points early after BMT. In the study group 62% and 33% 
of the évaluable patients had no donor red cells detectable at 0.5 and 1 month after BMT, 
respectively. In the control group these percentages were 19% and 0% respectively (p<0.01). 
The median number of erythrocyte transfusions after BMT was 18 (range 6-64) in the ABO 
incompatible group and 10 (range 2-46) in the control group (p<0.001). 
Leukocyte and platelet recovery did not differ between the ABO incompatible group and the 
control group (data not shown). 
84 
Major ABO incompatible lymphocyte-depleted BMT 
Table I. Comparison of clinical data between the study and the control group 
Conditioning regimen 
TBI: 9Gy 
12 Gy 
anthracychnes 
(added to TBI 9 Gy) 
Indications for BMT: 
acute leukaemia 
CML 
others 
Age (years): 
<40 
г 40 
Donors. 
histocompabble sibling 
others 
GVHD (grade): 
0-1 
г II 
major ABO 
incompatible BMT 
η = 30 
22 
6 
18 
14 
14 
2 
21 
9 
26 
4 
23 
7 
control group 
η = 58 
39 
18 
35 
29 
17 
12 
30 
28 
54 
4 
41 
17 
NS 
NS 
NS 
NS 
NS 
NS 
No significant differences of clinical variables between the groups were found 
(Fisher's exact test). 
Table II. Donor erythrocyte repopulation in time 
Time major ABO incompatible BMT 
(months) % donor erythrocytes 
n 1 ) mean SD2 ' 
control group 
% donor erythrocytes 
n " mean SD2 ' 
0.5 
1 
2 
3 
6 
26 
30 
27 
25 
25 
0.04 
1.73 
18.02 
38 65 
73.93 
0.07 
2.66 
20.47 
32.25 
31.29 
54 
54 
50 
51 
51 
0.23 
5.26 
29.64 
55 93 
83.93 
0 56 
4.81 
14.76 
22 02 
18 69 
p<0.01 
p<0.01 
p<0 01 
p=0 03 
p=0.2 
11
 number of evaluations 2' standard deviation 
Delayed onset of erythropoiesis of at least 2 months after BMT 
Eight patients in the ABO incompatible group (recipients blood group O, grafts blood group 
A) had no detectable donor erythrocytes up to 2 months after BMT (UPN 70, 83,100, 126, 162, 
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199, 253, 281). In this same time period percentages of recipient erythrocytes in the six out of 
eight patients with a recipient marker (UPN 83 and 281 had no recipient marker) were progres­
sively decreasing. In these eight patients leukocyte counts >1,0x109/l were reached at a median 
of 29 days after BMT (ranging from 19 to 35 days). Patient UPN 199 died of cerebral haemorrhage 
while hypertensive due to CsA intoxication. At the time of death, 2 months after BMT, the platelet 
count was still below 20x109/I. In the remaining patients a platelet concentration of > 20x10s/I 
without transfusion support was reached at a median of 21 days with a range of 18 to 116 days. 
Data on these patients are given in Table III. 
Table III. Data on 30 major ABO incompatible patients 
pretransplant erythrocyte 
UPN anti-Α or anti-B titers leukocytes1' platelets1' time to onset of transfusions 
|gM kjG >1.0x108/l >20x109/l erythropoiesis2' (no.) 
delayed onset of erythropoiesis (n=8): 
70 
83 
100 
126 
162 
199 
253 
281 
median 
32 
256 
32 
512 
64 
128 
32 
64 
64 
512 
512 
128 
16000 
64 
1024 
128 
2048 
512 
30 
33 
19 
21 
30 
35 
28 
22 
29 
19 
116 
23 
18 
21 
— 
19 
27 
21 
5.5 
3 
3.5 
7 
4 
NE 
6 
>9 
5.5 
36 
42 3) 
15 
37 
29 
28 s' 
49 
64 3) 
37 
timely onset of erythropoiesis (n = 22): 
median 64 16 20 25 1 16 
range 4-512 1-512 10-29 11-50 0.5-2 6 - 3 0 
11
 days after BMT a months alter BMT ''unti death 
NE = not évaluable, patent died 2 months after BMT 
UPN 83 developed grade II acute GVHD of the skin 3 weeks after BMT. Treatment consisted 
of addition of corticosteroids to the CsA. While tapering off these drugs she developed limited 
chronic GVHD of the gut. Two months after BMT a bone marrow aspirate showed active 
myelopoiesis, absent erythropoiesis and no megakaryocytes. Three months after BMT the 
percentage of donor erythrocytes was 0.22. At that time point erythropoiesis in the marrow was 
active but the number of megakaryocytes was still low. She remained erythrocyte transfusion 
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dependent with 0.07% of donor erythrocytes 4 months after BMT. Platelet counts never rose above 
50x109/l. She died of CMV pneumonitis 6 months after BMT. 
UPN 100 remained transfusion dependent up to 3 months after BMT. During this period there 
were no signs of acute GVHD. Bone marrow morphology at land 3 months showed PRCA. At 
3 months after BMT no donor erythrocyte percentage was available. At 3.5 and 4 months after 
BMT these percentages were 4.2 and 19.2, respectively. He is in remission of ALL with 100% 
donor erythrocytes and no recipient erythrocytes at 6.5 years after BMT. 
UPN 70 had no detectable donor erythrocytes up to 3 months after BMT with the picture of 
PRCA in the marrow aspirate. The patient did not suffer from acute GVHD. Treatment with cortico-
steroids was started 4.5 months after BMT in an attempt to stimulate donor erythropoiesis. One 
month later the percentage of donor erythrocytes was 36 and this gradually increased to 100% 
afterwards. This patient is in complete hematological, cytogenetic and molecular remission of CML 
7 years after BMT. 
UPN 126 had no detectable donor red cells up to 6 months after BMT reflected by PRCA in 
the marrow aspirates performed 1, 3 and 6 months after BMT. Cytogenetic analysis of the bone 
marrow performed 6 months after BMT showed only cells of donor origin. Neither acute nor chronic 
GVHD occurred. The last erythrocyte transfusion was required 6.5 months after BMT. Nine months 
after BMT, 78% donor erythrocytes were present. This patient died of marrow and CNS relapse 
of AML 10 months after BMT while only donor, but no recipient red cells could be demonstrated. 
UPN 162 had PRCA in the marrow aspirate and no detectable donor erythrocytes 3 months 
after BMT. In these first months he was treated with corticosteroids for acute GVHD grade I limited 
to the skin. From 4 months onwards the percentage of donor cells started to rise to 100% at 1 
year after BMT. Cytogenetic relapse of CML occurred 1 year later. 
UPN 253, transplanted for eosinophilic syndrome, had no detectable donor erythrocytes until 
6 months after BMT at which time point the percentage was 2 and erythropoiesis could for the 
first time be observed in the marrow aspirate. Acute GVHD did not occur. He died of Aspergillus 
sepsis complicating de novo chronic GVHD of the liver 9.5 months after BMT. 
In UPN 281, transplanted with an unrelated graft for CML in first accelerated phase, donor 
erythrocytes were never demonstrable during follow up. She developed acute GVHD grade I limited 
to the skin which was successfully treated by addition of corticosteroids to the CsA. Because of 
limited chronic GVHD of the skin and gut, treatment with low-dose CsA was continued. Bone 
marrow morphology at 6 and 9 months after BMT showed PRCA. Cytogenetic and molecular 
remission existed at these observation points. In situ hybridization showed only donor cells. 
Relapse with blast crisis occurred 11 months after BMT. The patient died 1 month later. 
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All eight patients with delayed onset of erythropoiesis had blood group О in contrast to 12 out 
of 22 patients in the major ABO incompatible group with timely onset of erythropoiesis (p=0 02) 
Course of recipient erythrocytes in the study and control group 
The course of recipient erythrocytes after BMT could be studied in 20 patients in the study group 
and 36 patients in the control group The same rates of decreasing percentages of recipient 
erythrocytes were observed in the control group and in the study group, both in patients with 
delayed and in patients with timely recovery of donor erythropoiesis Six months after BMT 
recipient erythrocytes sbll were detectable in eight out of 17 patients in the study group and nine 
out of 32 patients in the control group (p=0 1) At that time point means and standard deviations 
of percentages of recipient erythrocytes were 0 23 ± 0 2 and 0 48 ± 0 47 for the study and the 
control group respectively (not significantly different) This data implicates a high percentage of 
mixed erythrocyte chimensm in both the major ABO incompatible and the control group 
Anti-Α and anti-B antibody titers in major ABO incompatible BMT 
Anb-A and anti-B titers before BMT were compared between the eight patients with delayed 
onset of donor erythropoiesis and the remaining 22 patients in the major ABO incompatible group 
(Table III) No significant difference in saline (IgM) titers before BMT could be observed between 
the two groups However, IgG titers before BMT were significantly different (p<0 01) between the 
groups This difference still existed after leaving out the IgG titre of 16000 of UPN 126 (p=0 01) 
In the 22 patents, mentioned above, a sharp decrease of anti-Α and anti-B antibodies IgM as 
well as IgG, was observed after BMT Three months after BMT IgM and IgG titers were measured 
in 20 out of 22 patients At that time point the IgM titer was zero in 14 patients and vaned from 
one to eight in the remaining six patients The IgG titer was zero in 11 patients and vaned from 
one to eight in the other nine patients The mean antibody titers (IgM and IgG) of the 22 patients 
before and in the first 6 months after BMT are shown in Figure 1A and 1B 
The course of the anb-A and anb-B anbbodies after BMT in the eight patients with delayed onset 
of donor erythropoiesis also is shown in Figure 1A (IgM) and 1B (IgG) Within the first month after 
BMT an increase of titers was observed in some patients and stable titers in other patients Only 
UPN 83 showed a three-step decrease of titers in this time penod Three months after BMT all 
seven patents alive sbll had detectable anbbody titers in a range higher than the other 22 pabents 
in the ABO incompatible group 
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before 2 3 4 
Time (months) 
before 1 2 3 4 
Time (months) 
• UPN70 
+ UPN 83 
O UPN 100 
G UPN 126 
x UPN 162 
O UPN 199 
Δ UPN 253 
X UPN 281 
— mean of η = 22 
Fig 1 Course of ABO antibody titers IgM (A) and IgG (B) after major ABO incompatible BMT 
(A) shows the mean course of anibody titers (IgM) in 22 patients with timely recovery of donor erythropoiesis after 
major ABO incompatible BMT (bold line), the eight patents with delayed onset of erythropoiesis are shown 
separately, (B) shows the same course for IgG 
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Discussion 
Delayed onset of donor erythropoiesis and persistence of anti-Α or anti-B hemagglutinins are 
well known phenomena after major ABO incompatible BMT5 9 1 0 After red cell depletion of the 
graft Sniecinski et a l 9 observed delayed onset of erythropoiesis >40 days after BMT and 
persistence of anti-Α and anti-B antibodies >120 days in 10 out of 66 (15%) major ABO 
incompatible transplantations In a later study on major ABO incompatibility these complications 
occurred in nine out of 5Θ (16%) patients while the overall incidence of immunohematological 
complications was 21% Senous associated morbidity was not observed however and erythro­
poiesis became normal in all but one patientю In a study by Gmur et al1 1 three out of 15 major 
ABO incompatible transplants (20%) developed PRCA lasting 5 to β months 
In our study erythropoiesis was delayed in the 30 patients who received a major ABO incompa­
tible graft compared to an ABO compatible or minor ABO incompatible control group In eight out 
of 30 patients, donor erythrocytes were still undetectable 2 months after BMT Six out of eight 
patients developed the clinical picture of PRCA lasting from 3 5 to 9 months after BMT Except 
for a transient positive direct antiglobulin test in UPN 70 no clinical or laboratory signs of hemolysis 
were observed at the beginning of erythrocyte production in five of the six PRCA patients In one 
patient donor erythrocytes were never detectable after BMT UPN Θ3 had 0 22% of donor 
erythrocytes 3 months after BMT Major ABO incompatibility may have played a role in the delayed 
onset of erythropoiesis in this patient but GVHD and recurrent viral infections can not be ruled 
out as additional causative factors 
All patients with delayed onset of donor erythropoiesis were blood group О which was 
significantly more often than in the major ABO incompatible patients with timely onset of ery­
thropoiesis Most cases of PRCA after BMT reported in the literature involve patients with blood 
group О and donors with blood group A or В although 2 cases of a recipient with blood group A 
and a donor with blood group В and vice versa have been descnbed 1 0 1 1 2 1 и 
Twenty-two patients in the major ABO incompatible group had detectable donor erythrocytes 
within 2 months after BMT Pretransplant IgM anti-Α and anti-B antibody titers were identical and 
IgG titers were significantly lower compared to the eight patients with delayed onset of 
erythropoiesis Vanous reports in the literature did not agree on a correlation between pretransplant 
ABO antibody titers and the number of days posttransplant before onset of erythropoiesis51011 
In the 22 patients antibody titers decreased immediately after BMT and were undetectable or 
present in low titers at 3 months after BMT This is in agreement with the data of Gmur et al1 1 
in 11 patients with timely recovery of erythropoiesis after major ABO incompatible BMT They 
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described a progressive decrease and titers persistently £16 from day 32 onward The course 
of ABO antibodies after BMT was clearly different in seven out of eight patients in our study with 
delayed onset of erythropoiesis An early nse or persisting high titers (IgG more than IgM) were 
observed in this group A correlation between delayed onset of erythropoiesis and posttransplant 
nse or persistence of high (above 16) antibody titers was also described in recipients of a non-
lymphocyte depleted major ABO incompatible graft Only after a substantial reduction in these 
titers to a level of four to 16 erythrocyte production b e g a n 5 1 c m Delay in erythropoiesis can be 
explained by the interaction of anti-Α or anti-B antibodies with donor erythroid precursors 
expressing the A and/or В antigens2 3 2 4 
A study comparing the course of anti-donor ABO antibodies after BMT between recipients of 
elutriated and non-elutnated major ABO incompatible grafts was performed by Bar et a l я 
Although the number of patients studied was small, no evidence for prolonged persistence of anti-
donor antibodies in the elutnated group was found 
The incidence of immunohematologic complications and PRCA (20%) in our study is similar 
to the incidence reported in the literature 1 0 1 1 Theoretically one could have expected a higher 
incidence of immunohematological complications in our patients Firstly, all our patients received 
red cell depleted grafts instead of lowenng pretransplant ABO antibody titers in the recipient In 
the study by Gmur et al " 14 évaluable patients received an ABO incompatible graft Seven 
patients underwent large volume plasma exchange and seven patients received an erythrocyte 
depleted graft Timely recovery of erythropoiesis was observed in all but three patients who had 
received a red cell depleted graft Jin et al26 however found no difference in erythrocyte transfu-
sion requirements between recipients of a red cell depleted graft and patients who had plasma 
exchange or immunoadsorption before major ABO incompatible BMT Secondly, all our patients 
received a lymphocyte depleted graft in contrast to the patients reported in the literature Earlier 
studies in our patient population showed that lymphocyte depletion of donor marrow resulted in 
a high incidence of mixed chimensm and persistence of host lymphocytes27 2B However, 
cytogenetic evaluation of blood and marrow was usually not performed before 6 months after BMT 
In the major ABO incompatible patients of the current study cytogenetic analysis of the blood was 
not performed Cytogenetic analysis of the bone marrow 6 months after BMT showed no difference 
in mixed chimensm between the group with PRCA and without PRCA (data not shown) This data 
suggests that mixed chimensm of the bone marrow does not play a major role in the development 
of PRCA 
CsA was given as immunoprophylaxis posttransplant in all patients reported in the literature 
who developed PRCA after major ABO incompatible BMT 1 С И 2 2 1 ^2 8"3 3 in these studies CsA was 
administered alone or in combination with prednisone or a short course of methotrexate (MTX) 
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PRCA was never observed after the use of only MTX to prevent GVHD CsA acts primarily as 
an immunosuppressive agent on T-lymphocyte proliferation in response to pnmary antigen 
stimulation In the case of major ABO incompatibility T-lymphocytes are re-exposed to the 
stimulating A or В antigens In this setting CsA does not inhibit T-lymphocyte proliferation 
All our patients were treated with CsA In one patient with PRCA (UPN 100) erythropoiesis 
began while CsA was still administered In the other four patients erythropoiesis started 0 5 , 1 , 
2 and 3 months after cessation of CsA according to the treatment protocol In the three patients 
with PRCA desenbed by Gmur et al 1 1 erythropoiesis began during CsA treatment in one patient 
and 10 and 83 days respectively after conclusion of CsA in two patients Volm and Ruutu21 
described one patient recovenng from PRCA while still on CsA treatment In the case study by 
Ohashietal2 9 stopping CsA had no effect on the recovery of PRCA So, in our opinion CsA only 
plays a role in the possibility to develop PRCA after allogeneic BMT 
Treatment with corticosteroids for PRCA was not found to be beneficial102932 In our study UPN 
162,253 and 281 received corticosteroids for GVHD without apparent effect on erythro- poiesis 
Corticosteroids were administered to UPN 70 4 5 months after BMT in an attempt to treat PRCA 
No further erythrocyte transfusions were required One month afterwards 36% erythrocytes of 
donor ongin were present Spontaneous recovery can not be excluded as anti-Α antibody titers 
were clearly decreasing before corticosteroid treatment was started 
Treatment successes and failures in PRCA after BMT have been desenbed with plasma 
exchange1021 и з 2 and erythropoietin (EPO) ^ 3 0 3 3 A patient desenbed by Ohashi et a l M did not 
respond to EPO alone but erythropoiesis began after the addition of methylpredmsolone to EPO 
Gamma globulins were not found to be beneficial in two case reports X33 In two cases of PRCA 
treatment with anti-lymphocyte globulin resulted in restoration of erythropoiesis a 31 
Immunohematologic complications did not occur more frequently in recipients of major ABO 
incompatible marrow grafts, depleted of lymphocytes by counterflow centnfugation, compared 
to recipients of unmanipulated grafts Senous morbidity usually did not occur and immuno­
suppressive intervention was only occasionally necessary 
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Reconstitution of antibody response after allogeneic BMT 
Summary 
The generation of ABO hemagglutinins was used as a model to assess the tempo of 
reconstitution of antibody responses in recipients of elutriated (CCE) and nonelutriated (nonCCE) 
HLA matched bone marrow allografts. The study included 29 CCE recipients (10 major, six minor, 
and one major/minor ABO mismatched, and 12 ABO matched) and 40 nonCCE recipients (14 
major, 12 minor, two major/minor, and 12 matched). Plasma volume in the graft and in blood 
product transfusions was uncorrelated with changes in hemagglutinin titers and therefore was 
excluded as a significant source of antibody. Removal of graft lymphocytes by CCE did not result 
in prolongation of host-derived hemagglutinins in recipients of major ABO mismatched grafts. 
However, CCE resulted in a complete abrogation of the adoptive transfer of donor-derived antibody 
as detected in recipients of minor ABO mismatched grafts. Despite the absence of adoptively 
transferred donor immunity in recipients of CCE grafts, they had hemagglutinin levels comparable 
with those of recipients of nonCCE grafts by 6 months after transplantation. This demonstrates 
that recipients of elutriated marrow were competent to mount de novo responses at that time. 
The strong correlation between donor pretransplant hemagglutinin titer and recipient titer one year 
after bone marrow transplantation in recipients of nonCCE grafts suggests that even late after 
transplant, antibody remains the product of adaptively transferred memory cells in recipients of 
grafts containing large numbers of mature lymphocytes. 
Introduction 
Counterflow Centrifugal Elutriation (CCE) has emerged as an efficient and safe methodology 
for the removal of lymphocytes from bone marrow allografts.1"3 Lymphocyte depletion by this 
method effectively prevents acute graft-versus-host disease (aGVHD) in a lymphocyte dose 
dependent fashion in patients at high risk for this complication of bone marrow transplantation 
(BMT).3 Beyond simple depletion, CCE has proven to be a flexible technique capable of 
subfractionating lymphocytes into functionally distinct subpopulations.4'5 This may ultimately open 
the way for immunologic graft engineering. To realize this potential, it is important to closely 
document immune reconstitution in recipients of elutriated marrow and assess the impact of this 
procedure by comparison with patients transplanted with conventional allografts. By evaluating 
the expression of hemagglutinins we have implemented a simple, biologically meaningful method 
for the prospective evaluation of the development of T- and B-lymphocyte dependent immunity. 
Further, the availability of ABO mismatched donor/recipient pairs has enabled us to ascribe the 
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origin of particular antibody specificities uniquely to donor or recipient, and track the course of 
their disappearance or emergence as a function of graft type (elutnated or nonelutnated) and time 
after BMT Apart from the practical need to evaluate the effects of lymphocyte depletion on 
immune reconstitution, this methodology has also permitted us to dissect the relative contnbutions 
of the various components that can potentially influence the reconstitution of antibody responses 
These include passively transferred antibody, residual recipient responses, donor immune memory 
cells adoptively transferred in the graft, and lymphocytes of donor ongm that have differentiated 
within the host environment 
Materials and methods 
Mismatch definitions 
For the purpose of analysis, donor and recipient ABO disparities were divided into two groups 
depending on the direction of potential immune recognition Major ABO incompatibility was defined 
as a mismatch in which the recipient had the potentaat to express hemagglutinins directed against 
donor ABO antigens (ι e , recipient antidonor antibody) In minor ABO mismatch, the donor had 
the potentaal to express hemagglutinins directed against ABO antigens on recipient erythrocytes 
(donor antareapient antibody) Donor and recipient ABO blood group typing and expected antibody 
specificities are given for the different combinations of ABO mismatched BMT (Table I) 
Patient population 
Between December 1985 and January 1989, 64 patients underwent allogeneic BMT with an 
elutnated (CCE) H LA matched graft In 17 of these patients there was an ABO incompatibility 
between recipient and donor, 10 cases with major, six cases with minor, and one case with both 
major and minor incompatibility (Table I) The hemagglutinin titers of these 17 patients were 
compared with those of 28 recipients of HLA matched, ABO mismatched, nonelutnated grafts 
between 1983 and 1989 (Table 1) These 28 patients were participants in an immune reconstitution 
study, and frozen (-70°C) senal serum samples were therefore available All 17 recipients of 
elutnated bone marrow received cyclosponn A (CsA) to prevent graft rejection and graft-versus-
host disease (GVHD) Nineteen of the patients with nonelutnated grafts received CsA and nine 
patients were treated with cyclophosphamide (Cy) for posttransplant GVHD prophylaxis6 The 
median ages in these patient groups were 36, 21, and 22 years, respectively Patients were 
transplanted for chronic myelogenous leukemia (CML, eight CCE, seven nonCCE), acute 
myelogenous leukemia (AML, three CCE, eight nonCCE), acute lymphocytic leukemia (ALL, two 
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CCE, nine nonCCE); ηοη-Hodgkirïs lymphoma (NHL; three CCE, one nonCCE); Hodgkin's disease 
(HD: one CCE), and aplastic anemia (AA; three nonCCE). Patients in CCE and nonCCE groups 
could not be matched on age or disease status because the CCE group represented a high risk 
population participating in phase 1 trials.23 The pretransplant preparative regimen was determined 
by the patient's admission diagnosis. Patients with AML were treated with busulfan 4 mg/kg orally 
for 4 days followed by Cy 50 mg/kg/d for 4 days.7 Patients with AA were treated with Cy 120 mg/kg 
plus total body irradiation (TBI) or 200 mg/kg with or without TBI (12 Gy). The conditioning regimen 
for ALL, CML, HD, and NHL consisted of Cy 50 mg/kg/d for 4 days followed by TBI (12 Gy over 
4 days). An additional 12 recipients of ABO matched CCE grafts (with CsA chemoprophylaxis) 
and 12 patients who received ABO matched, nonCCE grafts plus CsA were also studied (Table 
1). 
Table I. Definition of expected antibody specificity by patient and donor blood group 
Blood group 
Donor Recipient 
Major ABO incompatible 
A О 
В О 
AB А 
AB В 
Major + minor ABO Incompatible 
А В 
В А 
Minor ABO incompatible 
О A 
О В 
О AB 
A AB 
В AB 
Totals 
ABO matched 
A A 
В В 
О О 
Totals 
Expected antibody sources and specificity 
Antirecipient Antidonor Donor and/or 
(donor-denved) (recipient-denved) Recipient-derived 
NA­
NA 
NA 
NA 
Antl-B 
AntJ-A 
Anb-A 
Antl-B 
An«-A, Anti-B 
Anti-B 
Anb-A 
NA 
NA 
NA 
Anb-A 
Anti-B 
Anti-B 
AntbA 
Anti-A 
Anb-B 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
Antl-B 
Anti-A 
NA 
NA 
NA 
NA 
Anb-B 
Anti-A 
NA 
NA 
NA 
Antl-B 
Anb-A 
Antl-A, Anb-B 
No of patients 
CCE nonCCE+CsA 
5 
4 
1 
1 
3 
2 
1 
17 
S 
2 
5 
12 
7 
2 
2 
1 
5 
1 
1 
19 
S 
7 
12 
nonCCE+Cy 
1 
2 
1 
4 
1 
9 
0 
'NA. not applicable. Antibodies of these specificities are not expected for the given recipient and donor ABO blood groups 
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For recipients of ABO incompatible transplants, samples were obtained before В MT and 2 
weeks, 4 weeks, 3 months, 6 months, and 1 year after transplant. For recipients of ABO matched 
grafts, recipient serum samples were examined before BMT, at 2 intervals early after BMT (2 
weeks and 4 weeks), and at one interval late after BMT (1 year in 22 of 24 cases). Sera were 
stored at -70°C before assay; all sera from a given patient were tested simultaneously. Donor sera 
obtained before marrow harvest were also assayed at the same time. A total of 362 patient and 
donor sera were assayed. 
воле marrow processing. 
All elutriated grafts were quantitatively depleted of erythrocytes (99.94% reduction) and 
contained no plasma.2 a A predetermined number of lymphocytes was intentionally added to the 
elutriated grafts. Twenty-two patients included in this study received 1x106 morphologic 
lymphocytes/kg ideal body weighty and seven received 0.5x106 lymphocytes/kg.3 Immuno-
phenotypic analysis of 11 grafts formulated at 1x106 lymphocytes/kg indicated a 97% reduction 
in T-cells (CD3 +) and a 96% reduction in B-cells (CD19+, HLA DR+) compared with the harvested 
marrow. Nonelutriated grafts were prepared according to the ABO status of the donor and 
recipient. To prevent massive hemolysis in ABO major mismatch, more than 95% of the 
erythrocytes were removed from the graft by apheresis, after which the bone marrow buffy coat 
was suspended in 50 to 100 mL of donor plasma.9 For minor ABO incompatibility, erythrocytes 
were not depleted, but approximately 90% of the plasma volume was removed from the graft and 
replaced with saline. Nonelutriated ABO compatible grafts contained approximately 3x1012 
erythrocytes and 600 to 700 mL plasma (mean harvest volume 1100 mL ± 300). 
Hemagglutinin titers. 
Hemagglutination was performed in 96-well U-bottom microtiter plates (Linbro 76-103-05, Flow 
Laboratories, McLean, VA). Sera were diluted г with saline (0.9%) or saline-dithiothreitol (OTT, 
0.01 mol/L) in 13 χ 75 mm polypropylene tubes and incubated for 30 minutes at 37°C. Serial two­
fold dilutions (eight steps, highest concentration = 1/4, volume = 50 pL/well) were made 12 times 
for each serum sample. Sera were titrated in duplicate against three reference cell types (A1, B, 
and O) under reducing (DTT) and nonreducing conditions. After addition of 50 pL of reagent red 
blood cells (RBCs; 3% in Alsever"s solution, Gamma Biologicals, Houston, TX), the plates were 
incubated at room temperature for 1 hour. The immunoglobulin M (IgM) titer was determined by 
direct agglutination in the nonreduced wells immediately after incubation. Endpoints were 
determined microscopically as the dilution giving an even carpet of cells with a slight ring at the 
edge. Sera remaining positive at the highest dilution (1/512) were retitrated with an initial serum 
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concentration of 1/128 Sera were considered positive for IgM only if incubation with DTT resulted 
in a four-fold or greater decrease in titer in the reduced wells After determination of the IgM titer, 
the plates were incubated for 30 minutes at 37°C and washed 6 times with saline, after which 
rabbit antihuman IgG (γ chain) antibody (BioRad, Rockville Center, NY, no 170-1222) was added 
to reduced and nonreduced wells (50 μ ι diluted 1/1000 in phosphate-buffered saline) The cells 
were gently pelleted by centnfugation (60g) for 15 seconds, and endpoint titers were determined 
microscopically The presence of IgG was confirmed if the addition of antihuman IgG to the 
reduced wells resulted in a four-fold or greater increase in titer The efficacy of washing to remove 
unbound IgG was confirmed in each assay by the addition of IgG sensitized Rh(D) positive 
erythrocytes (Coombs control cells, strong, 50 μ ι , 3% suspension/well, Gamma Biologicals) to 
negative wells containing the highest serum concentration Agglutination of sensitized RBCs 
indicated removal of extraneous IgG and confirmed the activity of the antiglobulin 
The absence of agglutination of О erythrocytes ruled out the presence of "irregular" 
hemagglutnatng antibodies A standard reference 0 + serum was run with each assay to ensure 
comparability of results Titers were adjusted according to the known titer of the standard These 
corrections were never more than one two-fold step 
Statistical analysis 
Statistical analysis was performed using SYSTAT 10 Hemagglutinatmg antibody titers were 
approximately log-normally distnbuted as determined by probability plots (SYSTAT GRAPH 
module) Accordingly, log transformations were made before the calculation of descriptive statistics 
or application of parametric analyses Arbitrary two-fold units were used, where 1 represents a 
titer of 1/4, 2 a titer of 1/8, etc The generalisation for this relationship is reciprocal titer = 2 ( x " 1 ) 
χ 4, where χ is the titer in arbitrary two-fold units and 4 is the reciprocal initial serum concentration 
For parametric analyses (means, Student's t-test, analysis of variance, linear regression) 
undetectable antibody levels (ι e , titers less than 1/4) were treated as 1/2 (0 in two-fold units) 
Analysis of vanance (ANOVA) and linear regression were performed using the MG LH module, 
descriptive statistics and Student's t-test were performed using the STATS module Pearson's 
χ
2
 was calculated in the TABLES module Graphics were created using SYGRAPH 11 
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Results 
Reference ranges for the hemagglutinin assay. 
The sensitivity and specificity of the assay were characterized with a series of 132 paired 
donor/recipient sera obtained before BMT. The distribution of donor and recipient titers by 
specificity and isotype are shown in Fig 1. IgM titers of both specificities were log-normally 
distributed. For both anti-Α and anti-B antibodies, IgM was a better indicator of subject ABO 
phenotype than IgG. Of 75 sera expected to be positive for anti-Α antibody, 74 (99%) had IgM 
titers ;> 1/4 and 63 (84%) had IgG titers ;> 1/4. Of 101 expected anti-B sera, 96 (95%) had 
detectable IgM titers, and 63 (62%) had detectable IgG. The geometric mean reciprocal titers 
(minus and plus the sample standard deviations) were 45 (10, 196), 39 (5, 277), 31 (7,127), and 
11 (2, 60) for anti-Α IgM, anti-Α IgG, anti-B IgM, and anti-B IgG, respectively. 
No "irregular" or inappropriate antibodies were detected in this series. None of 132 sera 
agglutinated О erythrocytes. Similarly, in none of 89 possible instances were inappropriate 
specificities detected (e.g., anti-Α antibody in an A type individual). 
Transfusions. 
Packed RBCs contain less than 10 mL of plasma per transfusion unit and were therefore 
considered not to be of influence on hemagglutinin titers. Intravenously administered gamma 
globulins, plasma, and platelet transfusions have higher Ig content and therefore could conceivably 
affect hemagglutinin titers through passive antibody transfer. To determine whether antibody titers 
could be affected by transfusion history, we examined the frequency of blood product admini­
stration in the first 3 months after BMT, the period during which maximal blood product support 
was required. A total of 45 patients receiving ABO mismatched BMT were studied. Platelet trans­
fusions were divided in two categories, first choice or washed platelets and second choice or 
platelets of unknown ABO phenotype. First choice platelets are usually of AB phenotype or of an 
ABO phenotype lacking the antidonor antibody in major ABO incompatible BMT or the antirecipient 
antibody in minor ABO incompatible BMT. For washed platelets, 95% of the plasma volume is 
replaced by saline. For some blood products, preparations were either of pooled donor origin or 
the ABO phenotype was not available retrospectively; these are designated "unknown." There 
were no significant differences in platelet transfusion history (both categories) between the CCE 
group, the nonCCE + CsA group, or the nonCCE + Cy group (Pearson's χ2 p>0.111, all 
comparisons). However, in the nonCCE + Cy group a significantly higher proportion of patients 
received plasma transfusions (7 of 9, 78%) than in the other two groups (5 of 36,14%, p=0 .001). 
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Fig 1 Distribution of hemagglutinin títere in BMT donor and recipient sera obtained before BMT (A and C) Distnbuuon 
of anti-A antibody in subjects of relevant phenotype (IgM and IgG. respectively) (B and D) Distnbuton of ant-B 
antibody Antibody titers are expressed in arbitrary two-fold units (see Matenals and Methods) Y axes show 
proportion per standard unit (count divided by the sample standard deviation) and the number of cases falling 
in each bar (count) Scaling to the proportion per standard units helps to compare the superimposed normal 
curves, which are based on the sample mean and standard deviation 
To determine whether administration of unwashed platelets elicited a rise in hemagglutinin titer 
corresponding to the ABO phenotype of the platelet product transfused, we evaluated the 
correlation between platelet dose and the difference in titers (IgM and IgG) before and after platelet 
administration. Data from all recipients of ABO mismatched grafts were divided into three time 
intervals: 0 to 2 weeks, 2 to 4 weeks, and 4 weeks to 3 months after BMT (Fig 2). 
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Fig 2. Lack of correlation between platelet dose and difference 'n relevant hemagglutrih titer after and before platelet 
administration. All platelets were of known blood type and were suspended in plasma. Changes in titer are 
expressed η two-fold steps. (O), Changes in titer measured between time 0 and 2 weeks; (β) 2 and 4 weeks; 
and ( · ) , 4 weeks to 3 months. To prevent data ponts from overlapping, a small uniform random error (jitter) was 
introduced to the location of each pont The parameters of the least squares linear regression are indicated. Exact 
(nonjrttered) values were used for the regression analyses. The Ines of best fit are shown. 
Platelet dose and change in relevant antibody titer (IgM or IgG) were uncorrelated. The greatest 
changes in titer were observed in recipients of nonCCE grafts in the first 2 weeks after В MT. 
The same methodology was used to look for a correlation between plasma dose and change 
in antibody titer. Because the ABO phenotype of plasma products was unknown, the influence 
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of each product on anti-Α and anti-B titers was evaluated (IgM and IgG) In agreement with the 
platelet data, no correlation was found (n=30, r=0 065, p=0 734, and r=0 026, p=0 892 for IgM 
and IgG, respectively) In fact, the recipient of the greatest number of plasma transfusions (122 
units from 2 to 3 months after BMT) had undetectable hemagglutinins (anti-Α and anti-B, IgM and 
IgG) at both 1 and 3 months after BMT 
Five recipients of ABO mismatched grafts (two CCE, three nonCCE) received intravenous 
gamma globulins in the first 3 months after BMT in a dose ranging from 7 to 90g No effect of 
this product could be detected in any of these five patients 
Major ABO incompatibility Recipient-derived antibody 
In major ABO mismatch, antidonor type antibody is of recipient origin and either represents 
preformed antibody or is the product of persistent host ongm B-cells (Table I) When the donor 
is A or В and the recipient is O, a second specificity may be produced, but its origin cannot be 
uniquely ascnbed to either recipient or donor In the case of major plus minor ABO mismatch (e g , 
A into B), recognition occurs in both directions (donor antirecipient and recipient antidonor) 
Therefore, a unique donor specificity may also occur 
Because major mismatched ABO specificities can be ascnbed uniquely to the recipient, analysis 
focused on the change in titer relative to pre-BMT levels In all patient groups, antidonor antibody 
fell as a function of time after BMT (Fig 3) The magnitude of antibody decrease in the first 3 
months after BMT did not differ between groups (p>0 2, Student's t-test, all compansons) Neither 
was the proportion of patients with persistent recipient derived antibody (IgM or IgG, > 3 months 
after BMT) significantly different between groups (p=0 176, Pearson χ2 test) One of the CCE 
patients demonstrated persistently high IgM and IgG antidonor antibody titers up to 1 year after 
BMT Among ail patients receiving nonelutnated grafts, five of 11 patients with an available serum 
sample at 6 months still had detectable antibody titers at that time point (IgM, IgG, or both) In 
no case could antidonor antibody be found at 1 year after BMT 
Minor ABO incompatibility Donor-denved antibody 
In minor ABO mismatch, antibody specificities can be detected that are uniquely attributable 
to donor B-cells (Table I) In none of the seven patients who received an elutriated, minor ABO 
incompatible graft could an antirecipient antibody be detected, either early (2 to 4 weeks, 14 
observations) or late after BMT (3 to 12 months, 13 observations) (Table II) In eight of 14 patients 
in the minor ABO incompatible, nonelutnated group, a transiently detectable antirecipient antibody 
was found early after BMT (28 observations) Donor denved antibody was IgM, IgG, or both and 
was independent of GVHD chemoprophylactic regimen Anti-Α was detected in 8 of 13 possible 
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instances (62%), and anb-B in 0 of 2 possible instances. Antirecipient antibody, when detected, 
was short-lived; none of the 14 patients had detectable titers 3 months or later after BMT (19 
observations). 
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Fig 3 Course of antdonor hemagglutinins in major ABO mismatched BMT Results are plotted for individual recipients 
grouped by graft type and GVHD chemoprophylans Reciprocal titers are shown on a log scale where negative 
samples (ι e , titer <Vi) are indicated as 1 (O), Ant-A and ( · ) , ant-B antibodies The locations of overlapping 
symbols were shifted slightly. 
Matched specificities: Antibodies derived from the donor, recipient, or both. 
In certain ABO mismatched combinations, antibody of a given specificity can be made by both 
donor and recipient, and thus cannot be uniquely attributed to either. In this respect they are 
comparable with antibodies elicited in ABO matched BMT (Table I). In the present analysis, these 
are referred to as donor and/or recipient-derived (DOR) antibodies. The effect of the graft type 
(CCE or nonCCE), GVHD chemoprophylaxis (CsA or Cy), or ABO match (match or mismatch) 
108 
Reconstitution of antibody response after allogeneic BMT 
on DOR antibody was determined at intervals before and after transplant by ANOVA. At no time 
interval did GVHD chemoprophylaxis or ABO match exert a significant influence on DOR titer (IgM 
or IgG, all ρ values >0.176). The DOR titers are shown as an function of time after BMT in Fig 
4. Early after BMT (2 to 4 weeks), recipients of nonCCE grafts had significantly higher DOR IgM 
titers compared with the CCE group (113 observations in 26 CCE and 31 nonCCE patients, 
p=0.001 by ANOVA). Although not statistically significant, a similar effect was seen in DOR IgG 
titers. Graft type dit not exert a significant effect on DOR IgM titers at other time intervals. In both 
graft types, the time to maximal DOR IgM titer preceded the time to maximal IgG titer. Maximal 
DOR titers (IgM and IgG) occurred later in recipients of elutriated grafts. 
Table II. Antirecipient antibody early after minor ABO incompatible BMT 
CCE» 
NonCCE + CsA 
NonCCE + Cy 
Uniq* 
491 
546 
562 
630 
706 
713 
857 
969 
412 
418 
464 
477 
498 
779 
Specificity' 
4xAnti-A 
ЗхАпб-В 
Anti-A 
Anti-A 
Anti-A 
Anti-A 
Anti-A 
Anti-A 
Anti-A 
Anti-A 
Anti-B 
Anti-A 
Anti-A 
Anti-A 
Anti-A 
Anb-A 
IgM/IgG* 
(2wk) 
<4/<4 
<4/<4 
128/512 
<4/8 
8/<4 
<4/<4 
4/<4 
<4/<4 
<4/8 
<4/<4 
4/8 
<4/<4 
<4/<4 
32/<4 
<4/<4 
IgM/IgG1 
(4wk) 
<4/<4 
<4/<4 
32/256 
<4/<4 
<4/<4 
<4/<4 
<4/<4 
<4/<4 
<4/<4 
<4/<4 
<4/8 
<4/<4 
<4/8 
<4/<4 
<4/<4 
Patent with antirecipient 
antibody / total No.5 
0/7 
5/8 
3/6 
* Patent unique number 
t Expected specificity of donor-denved, antirecipient antibody 
t Reciprocal titer of antirecipient antibody 
§ Number of patients having titers equal to or greater than 1 4 (IgM or IgG) 
I CCE 4 patents with expected pnenotype of ant-A and 3 patents with expected phenotype of anb-B, all had titers <1 4 
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Fig 4 Course of DOR hemagglutinins in recipients of CCE and nonCCE ABO matched and mismatched grafts Symbols 
represent mean titers, and bars indicate standard error of the means ( · ) , NonCCE, (O), CCE Mean titers are 
expressed in arbitrary two-fold units (see Materials and Methods) (A) IgM, (B) IgG 
To assess the possibility that passive transfer of antibody present in the graft could account 
for the higher DOR titers observed in recipients of nonCCE grafts, the change in DOR antibodies 
from time 0 to 2 weeks after BMT was compared between recipients of ABO matched and 
mismatched nonCCE grafts. The grafts administered to the former group contained 600 to 700 
mL donor plasma, whereas the latter contained little or no plasma. That no significant difference 
(IgM or IgG, p=0.178 and 0.378, respectively) was observed indicates that the infusion of several 
hundred milliliters of plasma did not detectably affect hemagglutinin titer. In the absence of stable 
B-cell mixed chimerism, DOR antibody should be exclusively of donor origin by 1 year after BMT. 
To determine whether normal hemagglutinin levels were attained, we compared DOR titers 1 year 
after BMT with the pretransplant donor titers of relevant specificity. In the case of О into О 
transplants where both A and В specificities counted as DOR, both anti-Α and anti-B titers for 
a given donor/patient pair were considered in the analysis. In recipients of both graft types DOR 
IgM was significantly lower than the relevant donor IgM titers (6.4-fold, n=46, p=0.000, paired 
t-test) In contrast, late DOR IgG levels and the relevant donor IgG titers were more comparable 
in both groups (1.7-fold difference, n=46, p=0.078). Despite the similarity between mean group 
DOR IgG levels, individual late DOR IgG titers were highly correlated with those of their respective 
donors in recipients of nonelutriated, but not elutriated, grafts (Fig 5). In recipients of nonCCE 
grafts, the intercept (-0.11 ± 0.76) and slope (0.82 ± 0.19) of the linear least squares line of best 
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fit are consistent with a direct correspondence between the magnitude of the pretransplant donor 
IgG hemagglutinin titer and that of the recipient late after BMT (Fig 5). 
Irregular antibodies. 
None of 230 post-BMT patient sera agglutinated О erythrocytes. Similarly, in no case were 
inappropriate specificities detected (e.g., anti-Α antibody in an A or AB recipient with an A or AB 
donor) 
1 - ЛЛ • O i l , r - O.S1, ρ - 0.191 » - -0.1 • 0.βι, г - Ο,ββ, ρ - 0.000 
Donor IgG titer before BMT Donor IgG titer before BMT 
Fig 5 DOR IgG hemagglutinins in recipients of CCE (A) and nonCCE (B) grafts Correlaten of DOR hemagglutinin 
measured at 1 year after BMT (y axis) with pretransplant donor IgG titers of the relevant specificity (x axis) 
(O), Anti-A IgG, ( · ) , anu-B IgG. The locations of overlapping symbols were shifted slightly. The parameters of 
the least squares linear regression are indicated The lines of best fit and 95% confidence intervals are shown 
DISCUSSION 
Hemagglutinins provide an excellent model for studying the reconstitution of antibody 
responsiveness after BMT. They are directed against well-characterized oligosaccharide units 
attached to carrier molecules,12 are absent in infants, and are elicited by exposure to antigens 
homologous to the ABH specificities found on human erythrocytes.13 These ubiquitous 
determinants are also present on a variety of gram-negative bacterial strains13 which are regularly 
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encountered by immunogenic routes,13 resultang in the generation of IgM, IgG and IgA isotypes " 
Consistent with previous results,15 we found the prevalence of anti-B hemagglutinins somewhat 
lower than that of anti-Α, in subjects of the relevant respective phenotypes (Fig 1 ) 
Applied to the problem of immune reconstitution after BMT, the use of ABO mismatched 
donor/reapient pairs allows one to distinguish between donor- and recipient-denved antibodies 
Further, comparison of the generation of donor-denved responses in recipients of unmampulated 
and elutnated grafts permits one to differentiate between donor-denved antibody responses 
conferred on the recipient by adoptive transfer of immune memory cells, and those generated 
de novo in the recipient environment 
Hemagglutinin titers are not significantly influenced by passive transfer of antibody present 
in blood products This was conclusively demonstrated by the lack of correlation between platelet 
(Fig 2), plasma, and gamma globulin doses with changes in antibody titers during the first 3 
months after BMT Similarly, although significantly more patients in the nonCCE + Cy group 
received plasma transfusions than those in the nonCCE + CsA group, their hemagglutinin titers 
were not elevated 
Major ABO incompatible BMT provided the opportunity to study the tempo of disappearance 
of recipient-denved antidonor antibody This parameter is of concern because lymphocyte 
depletion could result in prolonged survival of host immunity, a phenomenon that has been 
suggested to account for the increased incidence of graft rejection associated with this 
procedure16 The rate of disappearance of antidonor hemagglutinins is also of interest in itself, 
since significant immunohematologic problems have been associated with its persistence 17 
Although the number of patents available for study was small, we found no evidence for prolonged 
survival of recipient-denved antibody in recipients of elutnated grafts Only one recipient of 
elutnated marrow retained antidonor hemagglutinin by 1 year after BMT Restriction fragment 
length polymorphism analysis of his penpheral blood showed mixed chimensm at that time In 
recipients of nonCCE grafts, the use of CsA for aGVHD chemoprophylaxis may have enhanced 
survival of host ongin antibody, but the small number of observations in the Cy group precluded 
a definitive companson 
After minor ABO incompatible BMT we found an early transient appearance of donor-denved, 
anbrecipient antibody in eight of 14 recipients of conventional bone marrow grafts This contrasted 
sharply with recipients of elutnated grafts in whom we never detected this specificity The transient 
appearance of anbrecipient hemagglutinins in recipients of nonCCE grafts was not due to passive 
transfer because the plasma was removed from all minor ABO incompatible grafts Thus, it reflects 
the activity of mature donor lymphocytes infused with the nonelutnated graft These data are 
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consistent with our previous studies, which demonstrated that successful adoptive transfer of 
humoral- and cell-mediated responses to recall antigens required both donor-immune memory 
and early encounter with antigen in the recipient environment " Both of these conditions are 
fulfilled in the nonCCE group Transient donor antirecipient hemagglutinins have been descnbed 
previously in minor ABO incompatible conventional BMT 1β It has also been seen in minor ABO 
incompatible solid-organ transplants where it has been attnbuted to passenger lymphocytes 
present in the graft 192° In contrast to our findings using elutnation as a means of lymphocyte 
depletion, investigators who used T-cell-speofic monoclonal antibodies failed to abrogate the 
transient expression of donor-denved antirecipient hemagglutinins21и Thus, elimination of this 
response in recipients of elutriated marrow most likely reflects the removal of B- as well as 
T-memory lymphocytes Although it has been suggested that treatment with CsA favors the 
production of antirecipient antibody,18 our results and the results of others23 do not support this 
conclusion antirecipient antibody was found in three of six patients who received Cy rather than 
CsA immunosuppression In agreement with the results of others,1824 we did not detect 
antirecipient antibody in any of our patient groups at 3 months or later after BMT The 
disappearance of this specificity in recipients of nonCCE grafts, and its complete absence in 
recipients of CCE grafts, can be explained by the development of high-zone tolerance1824 for the 
recipient ABO antigen due to its wide distnbution in the tissues 12 Indeed, tolerance has been 
expenmentally induced in О type infants by repeated parenteral challenge with punfied A 
substance from birth to 8 months Ά The alternative explanation, that antirecipient antibody is 
produced but subsequently absorbed by recipient tissues, is less likely because this antibody was 
detected at maximal levels early after BMT when recipient ABO antigens are expressed on residual 
host erythrocytes as well as other tissues 
The existence of matched ABO specificities in ABO mismatched BMT permits the immune 
reconstitution of this relatively limited population to be compared with that of recipients of ABO 
compatible grafts Although these matched (DOR) specificities cannot in theory be uniquely 
ascnbed to donor or recipient, the kinetics of disappearance of recipient denved antibody (Fig 
3) suggest the donor ongm of DOR antibody late after transplant Early after transplant, DOR titers 
increased above pretransplant levels in both groups, with the nse in IgM titer preceding that of 
IgG The early increase in IgM titer was far more pronounced in the nonCCE group, most likely 
reflecting the adoptive transfer of mature B- and T-memory lymphocytes in the nonelutnated grafts 
This increase could not be attnbuted to passive transfer of antibody in the graft because DOR 
antibody was indistinguishable in the ABO-matched and -mismatched nonCCE groups, despite 
a substantially greater plasma volume in the nonCCE matched grafts Late after BMT, both IgM 
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and IgG levels decreased, but IgG levels remained comparable with donor pretransplant titers 
in both groups The stnking correlation between late DOR IgG in the nonCCE group, and the 
relevant pretransplant titers of their respective donors, suggests that even late after BMT, DOR 
IgG is still the product of adoptively transferred memory cells That DOR IgG titers in the CCE 
group were of comparable magnitude, yet uncorrected with individual donor titers, suggests the 
de novo generabon of the immunologic components required for antigen-specific IgG response 
in this group 
The pnmary goal of this study was to determine the influence of graft lymphocyte depletion 
by CCE on the reconstitution of antibody responses Taken together, these data bear on four 
important aspects (1) the fate of recipient ongin B-lymphocytes, (2) the significance of memory 
lymphocytes present in the graft, (3) the contnbution of T- and B-lymphocytes of donor ongin 
differentiating within the new host environment, and (4) the induction of immunologic tolerance 
to host antigens The removal of mature T- and B-lymphocytes from the graft did not result in a 
detectable prolongation of reapient-denved antibody production However, it did entirely abrogate 
adoptive transfer of antibody uniquely attnbutable to the donor, and retarded the expression of 
DOR antibody Despite this delay, recipients of lymphocyte depleted and conventional allografts 
had comparable DOR IgG titers by 25 weeks after BMT We have presented evidence suggesting 
that recipients of elutnated grafts generated this response de novo, while those who received 
unmanipulated grafts used memory lymphocytes transferred in the graft Finally, the adoptive 
transfer and subsequent loss of donor antirecipient antibody in recipients of unmanipulated grafts 
strongly suggests the induction of tolerance That these specificities were never observed in 
recipients of elutnated grafts highlights the fact that such "autoimmune" responses are far less 
likely when the majonty of immune cells have matured within the recipient environment 
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Summary 
Samenvatting 

Summary 
In Chapter 1, the introduction to this thesis, graft versus host disease (GVHD) is described as 
the major posttransplant complication of allogeneic bone marrow transplantation (BMT) GVHD 
is caused by donor T-lymphocytes in the marrow graft and its incidence can be clearly reduced 
by in vitro depletion of these lymphocytes Therefore all patients, transplanted at the University 
Hospital Nijmegen since 1981, have received allogeneic bone marrow partially depleted of T-
lymphocytes by counterflow centnfugation 
T-cell depletion is associated with an increased risk of leukemic relapse, especially in patients 
with chronic myeloid leukemia (CML) Patients with relapse of CML after BMT can be successfully 
treated with infusion of lymphocytes from the marrow donor, resulting in cytogenetic and molecular 
remission of CML in the majonty of the patients 
The two possibilities of allogeneic BMT across the ABO bamer are explained In major ABO 
incompatible BMT the recipient has the potential to express anb-A and/or antj-B antibodies against 
donor ABO antigens This can cause immunohematologic complications like delayed hemolytic 
anemia, delayed onset of erythropoiesis and pure red cell aplasia In minor ABO incompatible 
BMT anta-Α and/or ant-B antibodies of the donor may cause hemolysis of recipient erythrocytes 
early after BMT 
Mixed chimensm is the coexistence of recipient and donor lymphohematopoietic cells after BMT 
The incidence of mixed chimensm is clearly increased after BMT with T-cell depleted marrow 
compared to an unmanipulated graft The vanous techniques to distinguish donor and host 
lymphohematopoietic cells are briefly described In this thesis a sensitive fluorescent microsphere 
technique has been applied to measure recipient and donor erythropoiesis after BMT and donor 
lymphocyte infusions This requires determination of red cell antigenic differences between host 
and donor pnor to BMT and subsequently an adapted erythrocyte transfusion policy 
Chapter 2 describes an analysis of host and donor erythrocyte repopulation patterns after BMT, 
measured with the fluorescent microsphere assay All 91 patients, transplanted between 1981 
and 1988, received donor marrow, depleted of 98% of lymphocytes by counterflow centnfugation 
Complete red cell phenotypmg of patient and donor was performed before BMT to determine 
differing antigens, if present Both recipient and donor markers, recipient marker only, donor 
marker only or no markers were available in 64, 16, 9 and 11 percent of the BMT patients 
respectively The patents subsequently received erythrocyte transfusions of blood group О lacking 
the marker antigens The sensitivity level of the fluorescent microsphere assay is 0 0 1 % 
Thirty-seven patients were évaluable to monitor donor erythrocyte repopulation at one or more 
time points between 0 5 to 6 months after BMT Thanks to the sensitivity of the applied technique, 
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donor erythrocytes could be detected in 19 out of 22 évaluable patients (86%) two weeks after 
BMT in contrast to 15% using conventional agglutination techniques. At 6 months after BMT donor 
erythrocytes were detectable in 100% of the évaluable patients. From 0.5 to 6 months after BMT 
the percentages of donor red cells steadily increased from a median of 0.04% at 0.5 month to 
88.8% at 6 months. Recipients of major ABO mismatched transplantations showed a trend for 
delayed donor erythrocyte repopulation, which was significant at 3 months after BMT (p=0.03). 
A gradual disappearance of autologous erythrocytes in the first 6 months after BMT was observed 
in patients whose course was not complicated by relapse. At 6 months after BMT the percentage 
of autologous erythrocytes varied from 0 to 0.1% in the majority of these patients. 
Taking into account a 150-day survival time of recipient erythrocytes generated before BMT, 
mixed erythrocyte chimerism was defined by the coexistence of host and donor erythrocytes from 
6 months after BMT onward. In the 38 évaluable patients the incidence of mixed chimerism varied 
from 50 to 71% at various time points from 6 months onward. This high incidence can be explained 
by the T-cell depletion of the graft and the sensitivity of the fluorescent microsphere technique. 
No clinical evidence of leukemic relapse was found in 10 stable mixed chimeras with low 
percentages (<1) of autologous erythrocytes at different moments of analysis or in 6 mixed 
chimeras, who converted to complete donor chimeras. Mixed chimeras with high (>10), sometimes 
even gradually increasing, percentages of host erythrocytes did not relapse necessarily. 
In Chapter 3 the influence of the conditioning regimen on erythrocyte chimerism, GVHD and 
relapse after BMT has been studied. From May 1981 to January 1991 three consecutive conditio-
ning regimens were applied in 144 patients transplanted with marrow from a HLA identical sibling. 
The marrow graft was always depleted of lymphocytes by counterflow centrifugation. All three 
conditioning regimens consisted of cyclophosphamide and fractionated total body irradiation (TBI). 
In regimen A, applied in 49 patients, the total dose of TBI was 9 Gy. In regimen B, used in 65 
patients, the dose rate of TBI was increased and anthracyclines were added. In regimen С the 
total dose of TBI was increased to 12 Gy but no anthracyclines were administered (n=30). 
Age distribution was significantly different between the three patient groups with age at BMT 
increasing during the years. The absolute number of T-cells in the marrow grafts differed signifi­
cantly between the patients treated with regimen А, В and С However, compared to unseparated 
grafts the absolute number was very low in all patients in this study. 
In a multivariate analysis a significant influence of the conditioning regimen on the incidence 
of mixed erythrocyte chimerism was found (p=0.0004). Neither age nor the number of T-cells in 
the graft had a significant influence on this incidence. Intensification of the pretransplant regimen 
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resulted in a decrease of the incidence of mixed erythrocyte chimerism with incidences at 6 months 
after BMT of 73, 33 and 20% for regimen А, В and С respectively. 
The incidence and seventy of acute GVHD could be assessed in 139 out of 144 patients. The 
incidence of acute GVHD grade I or more was 15, 29 and 77% for regimen А, В and С 
respectively. Both age and the conditioning regimen influenced significantly the incidence of acute 
GVHD (p=0.017 and 00001 respectively). No significant influence of age, the conditioning regimen 
or the number of T-cells in the graft on the incidence of chronic GVHD could be detected by 
multivariate analysis. 
Combining the results of the three conditioning regimens, a relation between the presence of 
acute and chronic GVHD and the incidence of mixed erythrocyte chimerism could be established. 
The incidence of both acute and chronic GVHD was significantly higher in the group of complete 
donor than in the group of mixed chimeras (p<0.001 and p<0.01 respectively). 
The significance of mixed erythrocyte chimerism in CML and acute leukemia was studied. In 
CML patients a relation was found between the percentages of autologous erythrocytes from 6 
months after BMT onward and the occurrence of relapse. Patients, who did not relapse, were 
either complete donor chimeras or stable mixed chimeras with low (<0.5) percentages of recipient 
erythrocytes. High (>10) or increasing percentages of autologous erythrocytes were indicative 
of cytogenetic relapse. In acute leukemia this relation was not evident. 
To compare the probability of relapse between the conditioning regimens only good risk patients 
(acute myeloid or lymphoblastic leukemia in first complete remission and CML in first chronic 
phase) were studied. The probability of relapse was 43% in 32 and 18% in 43 good risk patients 
treated with regimens A and В respectively (p=0.07). Follow up was too short to draw conclusions 
about relapse in regimen С 
We conclude that intensification of the conditioning regimen resulted in a lower incidence of 
mixed erythrocyte chimerism, a higher incidence of acute GVHD and a trend to a lower relapse 
rate. 
Chapter 4 describes the treatment of seven patients with CML who relapsed after allogeneic 
BMT with a T-cell depleted graft. One patient received a second BMT with unseparated marrow 
from the same sibling donor 3 years after the first BMT. The other six patients were treated with 
donor leukocyte infusions from the original marrow donor. Five of them had a hematologic relapse 
of CML, one patient only a cytogenetic relapse. The interval between BMT and time of the 
infusions varied from 13 to 65 months in these patients. Nucleated cells from the donor were 
obtained by leukapheresis using a blood cell separator. The nucleated cells consisted mainly of 
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lymphocytes (70 to 85%) and monocytes (10 to 15%) The total dose of nucleated cells infused 
dunng the first course vaned from 0 34 to 1 8 χ 108/kg in the six patients Two patients, who did 
not respond to the first course received a second course with a double dose of donor leukocytes 
Chimensm was studied using erythrocyte and cytogenetic markers Monitonng of residual leukemic 
cells was performed by cytogenetic analysis of the Philadelphia (Ph) chromosome and by 
polymerase chain reaction (PCR) of the breakpoint cluster region/Abelson (BCR-ABL) fusion gene 
The patent treated with a second BMT achieved cytogenetic remission 6 months after BMT 
At that time point she was a complete donor chimera by cytogenetic analysis PCR of the BCR/ABL 
breakpoint molecules was negative 12 months after BMT Five patients with hematologic relapse 
achieved hematologic and cytogenetic remission 1 to 3 months after the donor lymphocyte 
infusions Four out of five patients achieved molecular remission 3 to 12 months after the 
infusions All five responding patients became complete donor chimeras by cytogenetic analysis 
and/or in situ hybridization Four out of 5 patients had a recipient erythrocyte marker A decrease 
in the percentage of autologous erythrocytes was observed in these patents with a disappearance 
in two of them 
All responding patients developed GVHD which was extensive in two patients The patient with 
cytogenetic relapse did not respond to two courses of donor lymphocyte infusions No signs of 
GVHD were observed in this patient 
We conclude that infusion of donor leukocytes is an effective treatment in patients with CML 
relapsed after BMT with a T-cell depleted graft Response always coincided with GVHD in our 
patients 
Chapter 5 is an analysis of erythrocyte repopulation in patients transplanted with major ABO 
incompatible, lymphocyte-depleted marrow Major ABO incompatibility between patient and donor 
existed in 44 out of 285 patients transplanted in Nijmegen from 1981 to 1994 Donor erythrocyte 
repopulation was évaluable in 30 out of 44 patents Fifty-eight patients transplanted with an ABO 
compatible or minor mcompatble graft served as a control group All marrow grafts were depleted 
of lymphocytes and erythrocytes by counterflow centnfugaton Less than 10e residual erythrocytes 
were present in the marrow graft Plasma exchange or plasma immunoadsorpton to reduce anti-A 
or anti-B antibody titers before BMT were never applied Erythrocyte repopulation was measured 
using the fluorescent microsphere method previously mentioned 
Donor erythrocyte repopulation was significantly delayed in the major ABO incompatible group 
compared to the control group up to 3 months after BMT (p¿0 03) Significantly more erythrocyte 
transfusions were required in the ABO mcompatble group (p<0 001) In the study group 62% and 
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33% of the évaluable patients had no donor red cells detectable at 0 5 and 1 month after BMT 
respectively In the control group these percentages were 19% and 0% respectively (p<0 01) Eight 
patients in the major ABO incompatible group had no detectable donor erythrocytes 2 months 
after BMT All eight patients had blood group О in contrast to 12 out of 22 patients in the major 
ABO incompatible group with timely onset of erythropoiesis Six patients (20%) developed pure 
red cell aplasia which resolved in five of them without therapeutic intervention 3 5 to 7 months 
after BMT 
Pretransplant anti-A and anti-B titers and the course of these antibodies after BMT were 
compared between the eight patients with delayed onset of erythropoiesis and the remaining 22 
patients in the major ABO incompatible group No significant difference in IgM titers before BMT 
could be detected between the two groups, while the IgG titers before BMT were significantly 
higher in the eight patients (p<0 01) In the 22 patients a steady decrease of anti-Α and/or anti-B 
antibodies IgM as well as IgG was observed after BMT This was in contrast with the eight patents 
with delayed onset of erythropoiesis, whose anti-Α titers were persistently high the first 3 months 
after BMT 
We conclude that the incidence of immunohematologic complications after major ABO 
incompatible BMT was not increased in our patients compared to data reported on recipients of 
unmampulated grafts despite the higher incidence of mixed chimensm Senous morbidity related 
to major ABO incompatibility did not occur Counterflow centnfugation is an effective technique 
to remove erythrocytes in case of major ABO incompatible BMT 
Chapter 6 descnbes the results of a study performed at the Johns Hopkins Oncology Center 
In this study the effect of lymphocyte depletion of the marrow graft by counterflow centnfugation 
on the expression of hemagglutinins after transplantation was studied ABO incompatibility existed 
in 17 out 64 patents transplanted with an elutriated graft between December 19Θ5 and January 
1989 Αηύ-Α and/or anti-B antibodies of these recipients before and at vanous time points after 
BMT were compared with the antibodies of 28 recipients of ABO incompatible non-elutnated grafts 
transplanted between 1983 and 1989 In addition anti-Α and/or anti-B antibodies were studied 
in 24 patients before and after ABO matched transplantation, 12 cases with elutriated and 12 
cases with non-elutnated marrow grafts Donor anti-Α and/or anti-B antibodies were measured 
in all cases Plasma volume in the graft and in blood transfusion products was uncorrected with 
changes in antj-A and/or anti-B titers and could be excluded as a significant source of antibody 
In both patient groups (elutnated n=11 non-elutnated n=16), recipient anti-donor, anti-Α and/or 
anb-B antibody fell as a function of time after major ABO incompatible BMT Although the number 
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of évaluable patients was small, no evidence for prolonged survival of host-derived hemagglutinins 
in recipients of elutriated grafts was found. 
In eight out of 14 recipients of a minor ABO mismatched non-elutriated graft, an antirecipient 
antibody could be detected early (2 and/or 4 weeks) after BMT. As plasma was removed from 
the graft the appearance of this antibody can not be explained by passive transfer. It reflects the 
activity of mature donor lymphocytes in the graft. This is supported by the fact that the antirecipient 
antibody was never detected in seven recipients of a minor ABO mismatched elutriated graft. 
Antirecipient antibody was never detected 3 months or later after elutriated nor after non-elutriated 
minor ABO mismatched BMT. This suggests the induction of tolerance for the recipient ABO 
antigen due to its wide distribution in the tissues. 
In certain ABO mismatched combinations, antibody of a given specificity can be made by both 
donor and recipient (DOR) antibody. This is a situation comparable with ABO matched BMT. No 
significant influence of ABO match (match or mismatch) on DOR titers before and at various time 
points after BMT could be detected. After pooling the data of ABO matched and mismatched BMT, 
DOR titers were compared between recipients of elutriated and non-elutriated grans. Early after 
BMT (at 2 and 4 weeks) DOR antibody titers increased more clearly in the non-elutriated group 
which reached significance in IgM but not in IgG titers. This difference is probably caused by the 
adoptive transfer of mature lymphocytes in the non-elutriated grafts. One year after BMT DOR 
antibody is most likely completely of donor origin. At this time point no significant difference of 
DOR antibody titers, IgM as well as IgG, could be detected between recipients of elutriated and 
non-elutriated grafts suggesting a de novo response in the elutriated group. 
General conclusion 
The microsphere technique is a very sensitive, reproducible method to monitor erythrocyte 
chimerism after allogeneic BMT. We used this technique in combination with other methods to 
study the influence of T-cell depletion and the intensity of the conditioning regimen on mixed 
chimerism and to relate mixed chimerism with the relapse risk. 
Moreover we studied kinetics of donor and recipient erythropoiesis in ABO incompatible 
allogeneic BMT and after donor lymphocyte transfusion for treatment of relapse after allogeneic 
BMT. 
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In hoofdstuk 1 van dit proefschnft wordt de omgekeerde afstotingziekte (GVHD) beschreven 
als de belangrijkste complicate van allogene beenmergtransplantatie (BMT) Deze omgekeerde 
afstotmgsziekte wordt veroorzaakt door de T-lymfocyten in het beenmerg van de donor De 
incidente ervan kan duidelijk worden verminderd door in vitro verwijdenng van deze lymfocyten 
uit het donorbeenmerg voor toediening aan de ontvanger Om deze reden hebben alle patiënten, 
die sedert 1981 in het Academisch Ziekenhuis Nijmegen zijn getransplanteerd, donorbeenmerg 
ontvangen waaruit het merendeel van de T-lymfocyten met behulp van tegenstroomcentnfugatie 
is verwijderd 
Verwijdenng van T-lymfocyten leidt tot een verhoogde kans op recidief van de leukemie, vooral 
bij patenten met chronisch myeloide leukemie (CML) Patenten met een recidief CML na BMT 
kunnen vaak met goed resultaat worden behandeld door toediening van lymfocyten van de 
beenmergdonor Deze behandeling leidt in het merendeel van de patenten tot een cytogenetische 
en moleculaire remissie van de CML 
De 2 mogelijke vormen van allogene BMT, waarbij een ABO bloedgroepverschil bestaat tussen 
ontvanger en donor, worden uitgelegd In het geval van een "major" ABO incompatibilité^ vormt 
de ontvanger ant-A en/of ant-B antstoffen tegen de bloedgroep van de donor Dit kan leiden tot 
immuunhematologische complicates zoals een uitgestelde hämolytische reactie, leidend tot 
bloedarmoede, vertraagd op gang komen van de donor erytropoiese en het volledig ontbreken 
van erytropoiese In het geval van een "minor" ABO incompatbilitert is het mogelijk dat ant-A en/of 
ant-B antstoffen van de donor in de vroege fase na transplantatie hémolyse van erytrocyten van 
de ontvanger veroorzaken 
Gemengd (mixed) chimensme na BMT is het verschijnsel van gelijktijdig aanwezig zijn van 
lymfohematopoietische cellen van zowel ontvanger als donor Na BMT met beenmerg waaruit 
de T-lymfocyten grotendeels zijn verwijderd, komt mixed chimensme duidelijk vaker voor dan 
na transplantate met onbehandeld beenmerg De verschillende technieken met behulp waarvan 
donor en ontvanger rymfohematopoietsche cellen onderscheiden kunnen worden, worden in het 
kort beschreven 
In dit proefschnft wordt een gevoelige techniek beschreven die gebruik maakt van 
fluorescerende microsferen (kleine bolletjes) om ontvanger- en donor-erytropoiese na BMT en 
infusie met donorlymfocyten te meten Dit vereist het vastleggen van de verschillen in bloedgroep-
antigenen tussen ontvanger en donor vóór BMT en vervolgens een aangepast erytrocyten-
transfusiebeleid 
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Hoofstuk 2 beschrijft een analyse van het verloop van de erytropoiese van de ontvanger en 
de donor na BMT, gebruikmakend van de fluorescerende microsferentechniek Alle 91 patiënten, 
die tussen 1981 en 1988 werden getransplanteerd, ontvingen donorbeenmerg waaruit met behulp 
van tegenstroomcentnfugatie 98% van de lymfocyten waren verwijderd Uitgebreide fenotypenng 
van patiënt- en donorerytrocyten werd voor transplantatie uitgevoerd om, indien aanwezig, 
verschillen tussen patient en donor aan te tonen In 64% van de patiënten was zowel voor de 
ontvanger als voorde donor een kenmerkend antigeen aantoonbaar, in 16% alleen een ontvanger-
kenmerk en in 9% alleen een donorkenmerk In 11% konden er geen onderscheidende kenmerken 
worden vastgesteld De patiënten werden vervolgens getransfundeerd met erytrocyten met de 
bloedgroep O, waarop de kenmerkende antigenen ontbraken Het gevoehgheidsniveau van de 
fluorescerende microsferentechniek bleek 0,01% 
Het opgang komen van de donorerytropoiese kon in 37 patiënten vastgesteld worden op een of 
meer tijdstippen tussen 0,5 en 6 maanden na transplantatie Dankzij de gevoeligheid van de 
gebruikte techniek was het al 2 weken na transplantatie mogelijk in 19 van de 22 evalueerbare 
patiënten (86%) donorerytrocyten aan te tonen Dit in tegenstelling tot de conventionele 
agglutmatie-techniek, waarbij dit slechts in 15% van de patiënten mogelijk was Zes maanden 
na transplantatie waren donorerytrocyten aantoonbaar in alle evalueerbare patiënten Het 
percentage donorerytrocyten nam geleidelijk toe van 0,04% na 2 weken tot 88,8% na 6 maanden 
De donorerytrocyten repopulatie kwam vertraagd op gang in ontvangers van een "major* ABO 
incompatibel transplantaat, indien vergeleken met de ovenge patiënten Alleen 3 maanden na 
transplantatie bleek dit verschil significant (p=0,03) BIJ patiënten, bij wie het beloop niet 
gecompliceerd werd door een recidief van de oorspronkelijke ziekte, nam het percentage autologe 
erytrocyten in de eerste 6 maanden na transplantatie geleidelijk af Zes maanden na transplantatie 
vaneerde het percentage autologe erytrocyten in het merendeel van deze patenten van 0 tot 0,1% 
Rekening houdend met een overlevingstijd van ontvanger-erytrocyten aangemaakt voor BMT 
van 150 dagen, definieerden wij mixed erytrocytenchimensme als de coëxistentie van ontvanger-
en donorerytrocyten vanaf 6 maanden na transplantatie De incidentie van mixed chimensme, 
vastgesteld op meerdere tijdstippen vanaf 6 maanden na BMT, vaneerde van 50 tot 7 1 % in 38 
evalueerbare patenten De verklanng voor deze hoge incidentie is enerzijds de verwijdenng van 
T-lymfocyten uit het transplantaat, anderzijds de hoge gevoeligheid van de fluorescerende 
microsferentechniek De 10 stabiele mixed chimeren met lage percentages (<1%) autologe 
erytrocyten op verschillende tijdstippen na transplantatie toonden geen aanwijzingen voor recidief 
Dit was evenmin het geval in 6 mixed chimeren die in het verdere verloop complete donor-
chimeren werden Ook de mixed chimeren met hoge (>10%) of zelfs stijgende percentages 
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autologe erytrocyten ontwikkelden niet altijd een recidief 
In hoofstuk 3 is de invloed van het conditionenngschema op het optreden van erytrocyten 
chimensme, GVHD en recidief na transplantatie bestudeerd Vanaf mei 1981 tot januan 1991 
werden achtereenvolgens 3 conditionenngsschema's toegepast bij 144 patiënten die getrans-
planteerd werden met beenmerg van een HLA-identieke broer of zus Het donormerg werd in alle 
gevallen met behulp van tegenstroomcentnfugatie ontdaan van het merendeel van de lymfocyten 
Alle 3 de conditionenngsschema's bevatten cyclofosfamide en gefractioneerde totale lichaams-
bestraling De totale dosis lichaamsbestralmg in schema A, toegepast in 49 patiënten, bedroeg 
9 Gy In schema B, toegediend aan 65 patiënten, werd het dosistempo van de totale lichaams-
bestraling verhoogd Bovendien werden in dit schema antracychnes toegevoegd Schema С 
bevatte geen antracydines doch in dit schema was de totale dosis lichaamsbestralmg 12 Gy Dit 
schema werd toegepast bij 30 patiënten Er was een significant verschil in de leeftijdsverdeling 
tussen de 3 groepen, aangezien de leeftijdsgrens voor transplantatie door de jaren heen toenam 
Het absolute aantal T-lymfocyten in het transplantaat verschilde eveneens significant tussen de 
3 patenten groepen Vergeleken met onbewerkt beenmerg was het absolute aantal T-lymfocyten 
echter zeer laag bij alle bestudeerde patiënten 
Een significante invloed van het conditionenngsschema op de incidente van gemengd 
erytrocytenchimensme werd vastgesteld met behulp van multivanant analyse (p<0,0004) 
Intensivering van het conditionenngsschema leidde tot een daling in de incidente van gemengd 
erytrocyten chimensme De leeftijd van de patient en het aantal T-lymfocyten in het transplantaat 
hadden geen invloed op deze incidente Zes maanden na BMT was de incidente respectievelijk 
73, 33 en 20% voor schema А, В en С 
De incidente en mate van acute GVHD kon bestudeerd worden in 139 van de 144 patiënten 
De incidente van GVHD graad I of meer bedroeg 15, 29 en 77% respectievelijk voor schema A, 
В en С Zowel leeftijd als het conditionenngsschema hadden een significante invloed op het 
optreden van acute GVHD (p=0,017 en 0,0001) De incidente van chronische GVHD werd noch 
door de leeftijd, noch door het condrtonenngsschema of het aantal T-lymfocyten in het donormerg 
beïnvloed 
Een relate tussen het optreden van acute en chronisch GVHD enerzijds en de incidente van 
gemengd erytrocytenchimensme anderzijds kon aangetoond worden, na bijeenvoegen van alle 
data van de dne schema's Zowel acute als chronisch GVHD kwamen significant vaker voor in 
de groep met compleet donorchimensme dan in de patenten met mixed chimensme (p<0,001 
en p<0,01) 
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De klinische relevantie van het optreden van mixed erytrocytenchimensme werd bestudeerd 
bij patiënten met CML en patiënten met een acute leukemie BIJ patiënten met CML bleek een 
relatie te bestaan tussen het percentage autologe erytrocyten vanaf 6 maanden na BMT en het 
optreden van een recidief van de ziekte Patienten die geen readier ontwikkelden, waren of 
compleet donorchimeren of stabiele mixed chimeren met lage (<0,5%) percentages ontvanger-
erytrocyten Hoge (>10%) of stijgende percentages ontvanger-erytrocyten duidden op het ontstaan 
van een cytogenetisch recidief Voor patiënten met een acute leukemie was deze relatie niet 
aantoonbaar 
Ter beoordeling van de recidiefkans na de verschillende conditionenngsschema's werden alleen 
patenten met een gunstige prognose (acute myeloide of lymfatische leukemie in eerste complete 
remissie en CML in eerste chronische fase) bestudeerd In 32 patiënten behandeld met schema 
A was de recidiefkans 43%, vergeleken met een kans van 18% in 43 patiënten na schema В 
(P=0,07) 
Gezien de korte follow-up konden WIJ geen uitspraak te doen over de resultaten van schema С 
Wij concluderen dat mtensivenng van het conditionenngsschema leidt tot een lagere incidentie 
van gemengd erytrocytenchimensme, een hogere madentie van GVHD en een tendens tot afname 
van de recidiefkans 
In Hoofdstuk 4 wordt de behandeling beschreven van zeven patiënten met een recidief CML 
na transplantatie met beenmerg waaruit de T-lymfocyten grotendeels waren verwijderd Een 
patent onderging een tweede BMT, dit keer met onbewerkt beenmerg van dezelfde donor, 3 jaar 
na de eerste transplantatie De overige zes patiënten kregen infusies met lymfocyten van de 
oorspronkelijke beenmergdonor Vijf van hen hadden een hematologisch recidief van de CML, 
de zesde patient had slechts een cytogenetisch recidief De periode tussen BMT en de toediening 
van lymfocyten vaneerde in deze patiënten van 13 tot 65 maanden De donorcellen werden door 
middel van aferese verzameld en bestonden voornamelijk uit lymfocyten (70-85%) en monocyten 
(10-15%) In de eerste cyclus van infusies vaneerde de totale dosis kemhoudende cellen van 0,34 
tot 1,8 χ 10B/kg bij de zes beschreven patiënten Twee patiënten, die geen reactie vertoonden 
op de eerste cyclus, werden opnieuw behandeld met een tweede cyclus infusies waarbij de dosis 
toegediende cellen twee maal zo hoog was Analyse van chimensme van de erytroide reeks vond 
plaats met behulp van de fluorescerende microsfeertechniek Chimensme werd ook bestudeerd 
gebruik makend van cytogenetisch onderzoek 
Het effect van de therapie op de CML werd vervolgd door cytogenetisch onderzoek naar het 
Philadelphia chromosoom en door moleculair onderzoek van de BCR/ABL translocatie De patient, 
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die een tweede BMT onderging was 6 maanden later in cytogenetische remissie. Cytogenetisch 
onderzoek toonde verder een compleet donor chimerisme aan. Twaalf maanden na BMT was 
bij moleculair onderzoek geen BCR/ABL translocatie aantoonbaar. De vijf patiënten met een 
hematologisch recidief kwamen 1 tot 3 maanden na de lymfocyten infusies in hematologische 
en cytogenetische remissie. Een moleculaire remissie werd in vier van de vijf patiënten bereikt 
3 tot 12 maanden na de lymfocyteninfusies. Alle vijf patiënten werden na de behandeling compleet 
donor chimeren bij cytogenetisch onderzoek en/of in situ hybridisatie. Bij vier patiënten met een 
kenmerkend antigeen voor ontvanger erytrocyten, daalde het percentage autologe erytrocyten 
na de lymfocyteninfusies. Dit leidde tot het volledig verdwijnen van autologe erytrocyten in twee 
van hen. Alle vijf patiënten die in remissie kwamen ontwikkelden GVHD waarvan twee in ernstige 
vorm. De patiënt met het cytogenetisch recidief toonde geen reactie op de behandeling. 
Wij komen tot de conclusie dat infusie van donoriymfocyten een effectieve therapie is voor 
patiënten die een recidief CML ontwikkelen na BMT met lymfocyten-arm beenmerg. Het anti-
leukemic effect ging bij onze patiënten altijd samen met GVHD. 
Hoofdstuk 5 beschrijft een analyse van het herstel van de erytropoiese in patiënten na trans-
plantatie met "major" ABO incompatibel beenmerg. "Major" ABO incompatibiliteit deed zich voor 
bij 44 van de 256 patiënten, die tussen 1981 en 1994 in Nijmegen getransplanteerd werden. In 
30 van deze 44 patiënten kon de donorerytrocyten-repopulatie geëvalueerd worden. De controle-
groep bestond uit een vergelijkbare groep van 58 patiënten die een ABO compatibele of "minor" 
ABO incompatibele transplantatie ondergingen. Door middel van de tegenstrooncentrifugatie 
werden zowel lymfocyten als erytrocyten uit het transplantaat verwijderd met als gevolg dat in 
het transplantaat na elutriatie minder dan 10° erytrocyten resteerden. Geen van de patiënten 
onderging voor BMT een behandeling met het doel de anti-A of anti-B titer te verlagen. De 
erytrocytenrepopulatie werd gemeten door gebruik te maken van de fluorescerende microsferen 
techniek. 
Het herstel van de donorerytropoiese bleek de eerste 3 maanden na BMT significant vertraagd 
in de "major" ABO incompatibele patiëntengroep, vergeleken met de controlegroep (p<=0,03). 
De patiënten in de "major" ABO incompatibele groep kregen ook significant meer erytrocyten-
transfusies (p<0,001). In de studiegroep hadden 62% en 33% van de evalueerbare patiënten geen 
aantoonbare donorerytrocyten 0,5 en 1 maand na BMT, vergeleken met 19% en 0% in de 
controlegroep (p<0,01). Acht patiënten in de "major" ABO incompatibele groep hadden 2 maanden 
na BMT nog geen meetbare donorerytropoiese. Al deze acht patiënten, bij wie de donorerytro-
poiese vertraagd op gang kwam, hadden bloedgroep O in tegenstelling tot 12 van de 22 patiënten 
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in de "major" ABO incompatibele groep bij wie de donor erytropoiese wel tijaig op gang kwam 
BIJ zes patiënten was er sprake van "pure red cell" aplasie, een beeld dat zich in vijf patiënten 
3,5 tot 7 maanden na BMT spontaan herstelde 
De anti-A en anti-B titers voor BMT en het verloop van deze antistofspecificaties na BMT, 
werden vergeleken tussen de acht patiënten met vertraagd op gang komende donorerytropoiese 
en de ovenge 22 patenten in de studiegroep Vóór transplantatie bestond geen significant verschil 
in de IgM titers tussen de twee groepen, terwijl de IgG titers voor BMT wel significant hoger waren 
in de acht patiënten (p<0,01) Na BMT werd in de groep van 22 patiënten een gestage daling van 
zowel IgM als IgG anti-A en/of anti-B titers geobserveerd Dit was duidelijk in tegenstelling met 
de andere acht patiënten van wie de anti-A titers de eerste 3 maanden na BMT hoog bleven 
De incidente van immuunhematologische complicaties na transplantatie met "major" ABO 
incompatibel beenmerg in onze patiënten, ondanks het frequenter voorkomen van "mixed" 
chimensme, bleek niet hoger dan de gerapporteerde incidenbe bij patiënten getransplanteerd met 
onbewerkt beenmerg Wij zagen geen ernstige morbiditeit gerelateerd aan de "major" ABO 
incompatibilité^ De tegenstroomcentnfugatie techniek bleek een effectieve methode om 
erytrocyten uit het transplantaat te verwijderen in het geval van "major" ABO incompatibilité^ 
Hoofdstuk 6 beschnjft de resultaten van een studie die uitgevoerd werd in het "Johns Hopkins 
Oncology Center" In dit onderzoek werd het effect van lymfocytenverwijdenng uit het beenmerg 
door tegenstroomcentnfugatie op de expressie van anti-A en/of anti-B antistoffen bestudeerd 
In 17 van de 64 patiënten, die van december 1985 tot januan 1989 getransplanteerd werden met 
beenmerg waaruit het merendeel van de lymfocyten was verwijderd, bleek sprake van ABO 
incompabbiliteit tussen donor en ontvanger De anti-A en/of anti-B titers van deze patiënten voor 
en na BMT werden vergeleken met die van 28 patiënten die tussen 19B3 en 1989 een ABO 
incompatibel, onbewerkt transplantaat ontvingen Tenslotte werden de anti-A en/of anti-B titers 
voor en na BMT bepaald van 24 ontvangers van een ABO compatibel beenmerg (12 onbewerkt 
en 12 met lymfocyten verwijdenng) In alle gevallen werden ook de anti-A en/of anti-B titers van 
de donors bepaald Er kon geen correlatie worden vastgesteld tussen het plasmavolume in het 
transplantaat en in de diverse bloedprodukten enerzijds en veranderingen in anti-A en/of anti-B 
titers anderzijds 
Na "major" ABO incompatibele BMT werd in beide groepen (elutnabe n=11, geen elutnabe n=16) 
een daling van de ontvanger anti-A en/of anti-B antistoffen gezien Er waren geen aanwijzingen 
voor persisterende ontvangerantistoffen in de elutnatie pabentengroep Hierbij moet aangetekend 
worden dat dit effect slechts in kleine patiëntengroepen werd bestudeerd 
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In de vroege fase na transplantatie (2 tot 4 weken) met een "minor" ABO incompatibel, onbe-
werkt beenmerg kon in acht van de 14 patiënten een antistof gericht tegen de ontvanger 
aangetoond worden. Passieve overdracht van deze antistof met het transplantaat kon uitgesloten 
worden, daar het plasma hieruit verwijderd was. De antistof is een produkt van volwassen 
donorlymfocyten in het transplantaat. Na "minor" ABO incompatibele transplantatie met beenmerg 
waaruit het merendeel van de lymfocyten verwijderd was (n=7), werd deze antistof gericht tegen 
de ontvanger nooit aangetoond. Het feit dat vanaf 3 maanden na BMT in geen van de patiënten 
deze antistof nog aantoonbaar was, zou verklaard kunnen worden door het ontstaan van tolerantie 
voor ontvanger A en/of В antigeen. 
In sommige situaties van ABO incompatibiliteit kan antistof met een bepaalde specificiteit zowel 
door ontvanger- als door donorlymfocyten (DOR antistof) geproduceerd worden. Deze situatie 
is vergelijkbaar met een ABO compatibele BMT. De DOR titers voor en na BMT bleken niet 
significant te verschillen tussen ontvangers van een ABO compatibel en een ABO incompatibel 
transplantaat. Na bijeenvoegen van alle data (ABO compatible en incomoatibel) werden de DOR 
titers van ontvangers van onbewerkt en lymfocyten-arm beenmerg met elkaar vergeleken. In de 
vroege fase na BMT (2 tot 4 weken) werd met name in de ontvangers van onbewerkt beenmerg 
een stijging van de DOR titers gezien. Dit zou verklaard kunnen worden door de aanwezigheid 
van volwassen lymfocyten in het transplantaat. Een jaar na transplantatie lijkt het redelijk te 
veronderstellen dat de DOR antistof door donorlymfocyten geproduceerd wordt. Op dit tijdstip 
was er geen significant verschil meer in DOR titers (IgM en IgG) tussen beide groepen. Dit feit 
suggereert dat de produktie van antistof ook in de elutriatie groep op gang was gekomen. 
Algemene conclusie 
De fluorescerende microsferentechniek is een gevoelige, reproduceerbare methode om 
erytrocytenchimerisme na BMT te onderzoeken. Wij pasten deze techniek naast andere technieken 
toe om de invloed van lymfocytenverwijdering uit het transplantaat en van de conditionering op 
het optreden van mixed chimerisme te bestuderen en om mixed chimerisme te relateren aan de 
recidiefkans. 
Verder bestudeerden wij de kinetiek van donor- en ontvanger-erytropoiese in het geval van ABO 
incompatibele BMT en na infusie van donorlymfocyten ter behandeling van een recidief CML na 
BMT. 
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STELLINGEN 
behorende bij het proefschrift 
"Studies on host and donor erythrocyte populations 
in recipients of T-cell depleted bone marrow 
or lymphocyte transfusions from allogeneic donors". 
Brigit MAM. Bär 
Nijmegen, 26 november 1996 
1. Analyse van erytrocytenpopulaties na beenmergtransplantatie is slechts 
mogelijk wanneer er een ruim uitgetypeerd bestand van bloeddonors 
beschikbaar is. 
2. Door het regelmatig met behulp van de fluorescerende microsferentechniek 
bepalen van percentages ontvanger-erytrocyten na beenmergtransplantatie 
voor chronisch myeloide leukemie, kan een uitspraak worden gedaan over 
het ontstaan van een cytogenetisch recidief. 
3. Een recidief chronisch myeloide leukemie na beenmergtransplantatie kan 
met succes worden behandeld door infusie met donorlymfocyten. Dit is de 
eerste succesvolle toepasshg van immuuntherapie bij kanker. 
4. De ncidentie van immuunhematologische complicaties na "major* ABO 
incompatibele transplantatie wordt niet nadelig beïnvloed door elutriatie van 
het beenmerg. 
5. De vraag of de afwezigheid van donor anti-A en/of antì-В antistoffen gericht 
tegen de bloedgroep van de ontvanger, vanaf drie maanden na "minor* ABO 
incompatibele beenmergtransplantatie, een gevolg is van tolerantie of 
absorptie, wordt ook in dit proefschrift niet opgelost. 
6. Behandelingsprotocollen zijn een groot goed mits er gemotiveerd van kan 
worden afgeweken. 
7. Mede door gebrek aan ervaren chirurgen is bij de stadiëring van maligne 
lymfomen de moderne beeldvormende diagnostiek te prefereren boven een 
laparotomie. 
8. In tegenstelling tot een theatervoorstelling wordt onderzoek vaak geconti-
nueerd door gebrek aan succes. 
9. Besluitvorming rond optimale versus maximale veiligheid van bloedtransfusie 
lijkt meer door angst voor media en publiek bepaald dan door wetenschap-
pelijke argumenten. 
(N.a.v. de Invitational Conference "Optimale versus maximale veiligheid van 
de bloedtransfusie-keten in Nederland", 11-9-1996) 
10. Een bloeddonor doet wonderen, een beenmergdonor is een wonder. 
11. Een arts zou zich regelmatig moeten realiseren wat het betekent om zelf 
patiënt te zijn. 
12. Eén hond is leuk, twee honden nog veel leuker. 
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